On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize that hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the third leading cause of cancer-related death, with the majority of cases occurring in the setting of underlying . While viral hepatitis remains the most prevalent risk factor, MASLD is the fastest-growing etiology and is notable for its ability to cause HCC in non-cirrhotic livers, particularly in patients with and obesity.
- •Understand the molecular drivers of hepatocarcinogenesis, which include chronic inflammatory stress, oxidative damage, and specific genetic alterations. The most frequent early event is a mutation in the TERT promoter, which facilitates telomere maintenance and cellular immortality, followed by mutations in TP53 (found in ~27% of cases) and activation of the Wnt/beta-catenin signaling pathway.
- •Identify high-risk populations requiring surveillance, specifically all patients with cirrhosis (Child-Pugh A or B) and certain non-cirrhotic HBV carriers (e.g., Asian males >40, Asian females >50, or those with a family history of HCC). In these groups, the annual incidence of HCC exceeds the 0.2% to 1.5% threshold where surveillance becomes cost-effective.
- •Note the impact of viral integration in HBV-related disease, where the virus can integrate into the host genome to drive malignancy even in the absence of advanced fibrosis. Low-level viremia (HBV DNA 20–2000 IU/mL) independently predicts poor outcomes, suggesting that viral suppression is critical for cancer prevention.
- •Consider the role of the gut-liver axis and the tumor microenvironment (TME) in disease progression. The TME in HCC is profoundly immunosuppressive, characterized by the recruitment of M2-polarized macrophages and the exhaustion of CD8+ T cells, which provides the rationale for modern immune checkpoint inhibitor (ICI) therapies.
Evaluation
- •Suspect HCC in any patient with known or chronic HBV who presents with new-onset hepatic decompensation, such as worsening , jaundice, or . Unexplained weight loss or right upper quadrant pain should also prompt immediate investigation.
- •Initiate surveillance with biannual (every 6 months) abdominal (US) combined with serum (AFP) levels. While US is the standard, its sensitivity is limited in patients with high BMI or advanced macronodular cirrhosis; in such cases, consider abbreviated MRI protocols.
- •Interpret AFP levels with caution; while a threshold of AFP >20 ng/mL is often used for screening, a level >100 ng/mL is highly suggestive of malignancy in high-risk individuals. Note that approximately 30-40% of HCCs are non-secretory and will present with normal AFP levels.
- •Order multiphasic contrast-enhanced CT or MRI (the preferred modality) if a screening US identifies a nodule ≥10 mm or if the AFP is rising. The imaging must include late arterial, portal venous, and delayed phases to capture the characteristic vascular signatures of HCC.
- •Apply the LI-RADS (Liver Imaging Reporting and Data System) criteria to standardize diagnosis. A lesion is classified as LR-5 (definitely HCC) if it demonstrates arterial phase hyperenhancement (APHE) plus one or more of the following: non-peripheral washout, an enhancing capsule, or threshold growth (≥50% increase in size within 6 months).
- •Differentiate HCC from other malignancies using the LR-M category. Lesions that appear malignant but lack the specific hallmarks of HCC (e.g., rim enhancement or targetoid appearance) may represent intrahepatic cholangiocarcinoma or combined HCC-cholangiocarcinoma and typically require biopsy.
- •Utilize the GALAD score (Gender, Age, AFP-L3, AFP, DCP) or the GAAD algorithm (Gender, Age, AFP, DCP) to refine risk stratification, especially in MASLD patients where ultrasound sensitivity is poor. Des-gamma-carboxy prothrombin (DCP) is particularly useful as it reflects abnormal prothrombin production by malignant cells.
- •Assess liver functional reserve objectively using the Child-Pugh score and the ALBI (Albumin-Bilirubin) grade. The ALBI grade is calculated as (log10 bilirubin [µmol/L] × 0.66) + (albumin [g/L] × -0.085) and provides a more granular assessment of liver reserve than Child-Pugh, which relies on subjective measures like ascites.
- •Evaluate for macrovascular invasion (MVI) and extrahepatic spread. Portal vein tumor thrombus (PVTT) is a critical prognostic factor that shifts the patient to an advanced stage (BCLC C) and usually precludes curative-intent surgery.
- •Rule out other causes of elevated AFP, including acute viral hepatitis flares or germ cell tumors, by correlating with liver enzymes and clinical history. If the diagnosis remains uncertain after high-quality imaging (LR-3 or LR-4), discuss the case in a multidisciplinary tumor board to decide between short-interval follow-up (3 months) or percutaneous biopsy.
- •Perform a baseline upper endoscopy to screen for in all patients being considered for systemic therapy with bevacizumab, as this agent increases the risk of variceal hemorrhage.
- •Obtain a chest CT and bone scan (or PET/CT in selected cases) if the primary liver lesion is large or if the patient is being considered for to ensure no extrahepatic disease is present.
Management
- •Adopt the Barcelona Clinic Liver Cancer (BCLC) staging system to guide treatment. Patients with BCLC 0 (very early) or A (early) are candidates for curative therapies, while BCLC B (intermediate) and C (advanced) require locoregional or systemic interventions.
- •Perform surgical resection for patients with a single tumor of any size, preserved liver function (Child-Pugh A), and no clinically significant portal (hepatic venous pressure gradient <10 mmHg). Aim for anatomical resection to eliminate potential micrometastases within the portal territory.
- •Refer for if the patient meets the Milan criteria (one lesion ≤5 cm or up to three lesions each ≤3 cm) and has decompensated cirrhosis (Child-Pugh B/C). Transplantation is the only therapy that treats both the tumor and the underlying pre-malignant cirrhotic environment.
- •Utilize thermal ablation, such as radiofrequency ablation (RFA) or microwave ablation (MWA), for BCLC 0 or A patients who are not surgical candidates. Ablation is highly effective for tumors ≤3 cm, though resection generally offers superior long-term recurrence-free survival.
- •Administer Atezolizumab 1200 mg IV plus Bevacizumab 15 mg/kg IV every 3 weeks as the first-line systemic therapy for unresectable HCC (BCLC C or TACE-refractory BCLC B). This combination has demonstrated superior overall survival compared to sorafenib.
- •Consider Durvalumab 1500 mg plus a single priming dose of Tremelimumab 300 mg (the STRIDE regimen) as an alternative first-line therapy, particularly in patients with a high risk of bleeding or contraindications to anti-angiogenic agents like bevacizumab.
- •Prescribe Lenvatinib as first-line monotherapy for patients who cannot receive immunotherapy. The dose is weight-based: 12 mg daily for patients ≥60 kg and 8 mg daily for those <60 kg. Monitor closely for hypertension and proteinuria.
- •Employ transarterial chemoembolization (TACE) for intermediate-stage (BCLC B) patients with multinodular disease and preserved liver function. TACE should be avoided in patients with portal vein thrombosis or Child-Pugh C cirrhosis due to the risk of hepatic infarction.
- •Implement Stereotactic Body Radiation Therapy (SBRT) as a bridging therapy for patients on the transplant waitlist or as a curative-intent option for small lesions (≤5 cm) in locations difficult to reach by ablation. A common dose is 40–50 Gy in 5 fractions.
- •Manage portal vein tumor thrombus (PVTT) with systemic therapy or, in selected cases, a combination of Hepatic Arterial Infusion Chemotherapy (HAIC) and radiotherapy. HAIC using the FOLFOX regimen has shown high response rates in locally advanced disease.
- •Monitor for treatment-related adverse events (trAEs) with immunotherapy, including immune-mediated hepatitis, colitis, and pneumonitis. If grade 3/4 toxicity occurs, hold the ICI and initiate high-dose corticosteroids (prednisone 1–2 mg/kg/day).
- •Avoid the use of immune checkpoint inhibitors in patients who have recently undergone liver transplantation, as there is a high risk of acute T cell-mediated allograft rejection and graft failure.
- •Achieve viral suppression in all patients with HBV-related HCC using tenofovir or entecavir, and treat HCV-related HCC with direct-acting antivirals (e.g., Sofosbuvir/Velpatasvir 400/100 mg daily) after achieving local tumor control to reduce the risk of recurrence.
- •Provide aggressive palliative care for BCLC D (terminal) patients, focusing on symptom management for ascites (diuretics or paracentesis), encephalopathy (lactulose/rifaximin), and pain. Median survival in this group is typically <3 months.
- •Schedule follow-up imaging every 3–6 months post-treatment to monitor for recurrence. Recurrence rates after resection are high (~70% at 5 years), often requiring salvage transplantation or repeat locoregional therapy.
Board Review — High Yield
- •Arterial Phase Hyperenhancement (APHE) — The classic imaging hallmark of HCC, reflecting the recruitment of unpaired arteries during hepatocarcinogenesis.
- •Milan Criteria — Defines transplant eligibility: 1 lesion ≤5 cm or up to 3 lesions each ≤3 cm, with no vascular invasion or extrahepatic spread.
- •Aflatoxin B1 — A potent carcinogen from Aspergillus fungi that causes a specific R249S mutation in the TP53 gene, common in sub-Saharan Africa and China.
- •LI-RADS 5 — A standardized imaging category that is 100% specific for HCC in high-risk patients, making biopsy unnecessary for diagnosis.
- •TERT Promoter Mutation — The most common genetic alteration in HCC, occurring early in the transition from dysplastic nodule to malignancy.
- •Fibrolamellar HCC — A rare variant occurring in young patients without cirrhosis, characterized by a DNAJB1-PRKACA gene fusion and a central stellate scar.
- •Heat-Sink Effect — The phenomenon where blood flow in large adjacent vessels carries away thermal energy, reducing the efficacy of RFA for perivascular tumors.
- •Sustained Virological Response (SVR) — Eradication of HCV reduces but does not eliminate HCC risk, necessitating continued surveillance in patients with advanced fibrosis.
Deep Dive — Evidence Details
Epidemiology and Global Risk Factors
- ▸HCC is the 3rd leading cause of cancer death globally, with a shifting etiology from viral hepatitis to MASLD [16, 17].
- ▸Low-level HBV viremia (20-2000 IU/mL) is an independent driver of hepatocarcinogenesis [5].
- ▸MASLD-related HCC frequently occurs in noncirrhotic livers, necessitating risk stratification beyond fibrosis staging [16].
Hepatocellular carcinoma (HCC) represents a critical global health challenge, currently ranking as the fifth most common cancer and the third leading cause of cancer-related mortality worldwide [17]D. While historically dominated by viral etiologies, the epidemiological landscape is shifting due to the rising prevalence of metabolic disorders [16]D. The incidence of HCC is highly variable by geography, often reflecting the endemicity of (HBV) and (HCV) [4]. For instance, in regions like Kyrgyzstan, HBV and HCV are the primary drivers of both and HCC, with specific attributable fractions varying by age and regional healthcare access [4].
Viral Etiology and Risk Modifiers
HBV remains the most prevalent risk factor globally [12]D. Recent evidence highlights that even low-level viremia (LLV), defined as HBV DNA between 20 and 2000 IU/mL, independently predicts poor outcomes and contributes to hepatocarcinogenesis [5]. This suggests that traditional treatment thresholds may overlook patients at significant risk. The mechanism involves complex molecular dysregulation, such as TRMT6-mediated m1A modification of CDK9 mRNA, which drives both viral replication and tumor progression [12]D. Furthermore, HBV-positive HCC often features a distinct population of GPX2+ cancer stem cells that recruit immunosuppressive B cells via the CCL26-CCR3 axis, facilitating tumor immune evasion [29]D.
In HCV-related disease, the risk persists even after achieving a sustained virological response (SVR), particularly in patients with co-existing metabolic dysfunction like (T2DM) [13]D. Chronic HCV promotes the formation of hepatic cancer stem cells through β-catenin-mediated EpCAM upregulation [27]D.
The Rising Impact of MASLD
(MASLD), formerly known as NAFLD, has emerged as a primary contributor to chronic liver disease and HCC [14]D[16]D. A critical epidemiological distinction of MASLD-related HCC is its occurrence in noncirrhotic livers [16]D. While the annual incidence in noncirrhotic MASLD is lower than in cirrhotic patients, the massive global prevalence of MASLD results in a high absolute number of HCC cases [16]D. Risk in these patients is amplified by metabolic comorbidities, specifically T2DM and obesity, which drive inflammation and fibrosis through pathways like the IL-33/ST2 signaling axis [14]D[17]D.
Genetic and Demographic Factors
Genetic susceptibility significantly influences the progression from infection or steatosis to malignancy. Meta-analyses of East Asian cohorts have identified specific susceptibility loci, including CD40 rs1883832 and C2 rs9267665 for HBV infection, and HLA-DPA1 rs3077 and HLA-DQB1 rs2856718 for HCC development [1]. In the context of steatotic liver disease, the PNPLA3 rs738409 variant remains a key genetic modifier of risk across the full spectrum of the disease [23]D.
Demographically, HCC shows a strong male predominance. In special populations, such as patients living with (HIV), HCC risk is compounded by chronic inflammation and immunosuppression [3]. HIV-positive patients often present with HCC at a significantly younger age (mean 45.8 years) compared to HIV-negative counterparts (mean 49.3 years) [3]. Additionally, HIV co-infection in chronic HCV patients is associated with a higher likelihood of HBV exposure (aOR 6.23), further elevating cancer risk [9].
Other Modifying Factors
Interestingly, non-hepatic conditions also modulate HCC risk. A nationwide Danish cohort study found that hyperthyroidism with low TSH levels is associated with a lower incidence of HCC (aHR 0.66, 95% CI: 0.29-1.47) [7]. Conversely, certain medications may offer protection; use has been linked to a reduced risk of primary liver cancer in MASLD patients, independent of age or the presence of cirrhosis [18]D.
Protocol for Epidemiological Risk Stratification in MASLD
Given the high prevalence of MASLD, clinicians must identify high-risk individuals who may develop HCC even in the absence of cirrhosis [16]D.
- Metabolic Screening: Identify patients with T2DM and obesity, as these are the strongest independent predictors of HCC in MASLD [16]D[17]D.
- Fibrosis Assessment: Utilize non-invasive biomarkers such as the FIB-4 index or MRI-based proton density fat fraction (MRI-PDFF) and magnetic resonance elastography (MRE) to stage liver stiffness [15]D[19]D.
- Genetic Profiling: Consider testing for the PNPLA3 rs738409 variant in patients with progressive steatosis to refine risk estimates [13]D[23]D.
- Viral Surveillance: Screen for occult HBV (HBcAb-positive/HBsAg-negative) or low-level viremia, especially in co-infected or high-risk populations [5][9].
| Risk Factor | Odds Ratio (OR) / Hazard Ratio (HR) | Evidence Level |
|---|---|---|
| HIV Co-infection (in HCV) | aOR 6.23 [9] | 2b |
| Low TSH (Hyperthyroidism) | aHR 0.66 [7] | 2b |
| Intravenous Drug Use | aOR 1.58 [9] | 2b |
| Cirrhosis (in HCV) | aOR 1.46 [9] | 2b |
| Low-level HBV Viremia | Independent Predictor [5] | 2b |
| PNPLA3 rs738409 Variant | Key Genetic Modifier [23]D | 5 |
Molecular Pathogenesis and Genetics
- ▸TERT promoter mutations are early, high-frequency drivers used to distinguish primary nodules from metastases.
- ▸The Wnt/β-catenin pathway is a central oncogenic axis regulated by DNASE1L3 and YTHDF1-mediated m1A methylation.
- ▸Immune evasion is achieved through G2E3-mediated CD8+ T cell suppression and GNPAT-driven M2 macrophage polarization.
The pathogenesis of hepatocellular carcinoma (HCC) is a complex, multi-step process driven by the accumulation of genetic mutations, epigenetic modifications, and chronic inflammatory stress. This transformation typically occurs within a pro-oncogenic microenvironment shaped by viral infections, metabolic dysfunction, and immune evasion [33]D[37]D[47]D.
Viral-Induced Oncogenesis
Viral hepatitis remains a primary driver of HCC through both direct and indirect mechanisms. In chronic Hepatitis B Virus (HBV) infection, the virus integrates into the host genome, leading to the expression of chimeric HBV/human RNA transcripts [53]D. These fusion transcripts can disrupt host gene function and promote genomic instability. Hepatitis D Virus (HDV), a satellite virus requiring HBV for replication, significantly accelerates this process [33]D. HDV infection induces severe chronic inflammation and oxidative stress, which increases "oncogenic pressure" and leads to rapid progression from fibrosis to cirrhosis and HCC [33]D.
In contrast, Hepatitis C Virus (HCV) drives hepatocarcinogenesis largely through epigenetic regulation. HCV infection dysregulates non-coding RNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) [38]D. These molecules often function as "molecular sponges," where lncRNAs or circRNAs sequester tumor-suppressive miRNAs, thereby promoting viral replication and malignant transformation [38]D.
Metabolic and Environmental Drivers
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH), are emerging as leading causes of HCC [39]D[41]D. The pathogenesis is fueled by modern diets high in ultraprocessed foods and sedentary lifestyles, which disproportionately affect specific ethnic populations [39]D.
Key metabolic mediators include:
- GNMT (Glycine N-methyltransferase): A critical S-adenosylmethionine (SAM)-dependent methyltransferase and tumor suppressor. Its downregulation, often mediated by miR-873-5p or miR-224, is strongly associated with both MASLD and HCC progression [34]D.
- Serotonin (5-HT): Both central and peripheral serotonin levels regulate hepatic metabolism and tissue remodeling, contributing to the progression of steatotic liver diseases toward malignancy [40]D.
- Circadian Disruption: Classified as a Group 2A carcinogen, the disruption of circadian cycles (e.g., via night-shift work or irregular eating) alters the expression of genes involved in metabolism and cell cycle control, facilitating HCC development [42]D.
The Genetic Landscape and Signaling Pathways
HCC is characterized by high tumor heterogeneity and specific driver mutations. TERT promoter mutations are among the earliest and most frequent genetic alterations, serving as a key mechanism for telomere maintenance and cellular immortality [51]D. These mutations are particularly useful in distinguishing multicentric occurrence from intrahepatic metastasis in multifocal HCC [51]D.
TP53 mutations are found in approximately 27% of HCC cases [55]D. In variants like hepatoid adenocarcinoma (HAC), TP53 mutations are associated with increased expression of PD-L1, potentially predicting responsiveness to immune checkpoint inhibitors (ICIs) [32]C. Furthermore, TP53-wild type tumors appear more sensitive to radiotherapy-induced abscopal effects through interferon (IFN) induction [55]D.
Key signaling dysregulations include:
- Wnt/β-catenin Pathway: This pathway is frequently activated in HCC. DNASE1L3 has been identified as a mediator that influences tumor growth via Wnt/β-catenin signaling [48]D. Additionally, the m1A RNA methylation reader YTHDF1 promotes malignancy by regulating the LRP5/Wnt/β-catenin axis [50]D.
- Alternative Splicing (AS): Dysregulation of AS, driven by metabolic dysfunction and viral hepatitis, generates aberrant mRNA isoforms that promote metabolic reprogramming, invasion, and drug resistance [37]D.
- Sialylation: Abnormal elevation of sialylation (hypersialylation) serves as a malignant marker and therapeutic target, influencing immune regulatory mechanisms [54]D.
Immune Evasion and the Tumor Microenvironment (TME)
The TME in HCC is profoundly immunosuppressive. G2E3 suppresses the tumor-killing function of CD8+ T cells by boosting the ubiquitination of CLCN2 [43]D. Simultaneously, GNPAT (glyceronephosphate O-acyltransferase) promotes immune evasion by activating the plasmalogen-PPARγ pathway, which drives the polarization of macrophages toward the pro-tumorigenic M2 phenotype [47]D. The gut-liver axis also plays a role; dysbiosis of the gut microbiota influences the TME through metabolic and immune interactions, affecting treatment response and prognosis [36]D[49]D.
Mechanism of Hepatocarcinogenesis
- Step 1: Etiological Trigger: Chronic injury from HBV/HCV, alcohol, or MASLD induces persistent inflammation and oxidative stress [33]D[39]D.
- Step 2: Genetic/Epigenetic Hit: Early mutations (e.g., TERT promoter) or epigenetic silencing of tumor suppressors (e.g., GNMT) occur [34]D[51]D.
- Step 3: Pathway Activation: Dysregulation of Wnt/β-catenin, RNA splicing, or m1A methylation drives uncontrolled proliferation [37]D[48]D[50]D.
- Step 4: Immune Evasion: The tumor recruits M2 macrophages and exhausts CD8+ T cells to bypass immunosurveillance [43]D[47]D.
- Step 5: Progression and Metastasis: Accumulation of further mutations (e.g., TP53) and metabolic reprogramming lead to advanced HCC [32]C[52]D.
| Driver/Mechanism | Molecular Target/Pathway | Clinical Significance |
|---|---|---|
| TERT Promoter | Telomere maintenance | Early oncogenic event; diagnostic for clonal origin [51]D |
| TP53 Mutation | Cell cycle/Apoptosis | Correlates with PD-L1 expression and RT sensitivity [32]C[55]D |
| HBV Integration | Chimeric HBV/Human RNA | Drives genomic instability and HBsAg production [53]D |
| GNMT | SAM-dependent methylation | Downregulated in MASLD/HCC; tumor suppressor [34]D |
| YTHDF1 | m1A RNA methylation | Activates LRP5/Wnt/β-catenin signaling [50]D |
| G2E3 | CLCN2 ubiquitination | Suppresses CD8+ T cell antitumor activity [43]D |
| GNPAT | Plasmalogen-PPARγ | Drives M2 macrophage polarization and immune evasion [47]D |
| Antibody | Target Antigen | Clinical Variant |
|---|---|---|
| MOG-IgG | Myelin Oligodendrocyte Glycoprotein | MOGAD (ICI-associated demyelination) [31] |
Surveillance and Early Detection
- ▸Biannual ultrasound combined with AFP, AFP-L3, and DCP biomarkers significantly improves early-stage HCC detection compared to ultrasound alone.
- ▸Non-cirrhotic MASLD and Fontan-associated liver disease represent emerging high-risk groups that challenge traditional cirrhosis-centric surveillance models.
- ▸Socioeconomic barriers and 'social risk phenotypes' are independent predictors of late-stage diagnosis and poor survival outcomes.
Surveillance for (HCC) is the cornerstone of in high-risk populations, as early detection significantly increases the likelihood of receiving curative-intent therapies such as resection, ablation, or [57][58]. Current international guidelines recommend a "one-size-fits-all" approach for at-risk individuals, though emerging evidence suggests a shift toward risk-stratified models to improve sensitivity and cost-effectiveness [65]D.
Standard Surveillance Protocols
The standard of care for HCC surveillance is biannual (every 6 months) abdominal (US), with or without the measurement of serum (AFP) [57][65]D. While US is widely accessible and non-invasive, its sensitivity for early-stage HCC is suboptimal, particularly in patients with high body mass index or advanced [59]. The addition of serum biomarkers to US has been shown to improve the detection rate of early-stage tumors compared to US alone [57].
Surveillance Implementation Protocol:
- Identify High-Risk Candidates: Screen all patients with (Child-Pugh A or B) and specific subgroups with chronic (HBV) or (HCV) [57][65]D.
- Biannual Screening: Perform abdominal US and serum AFP every 6 months.
- Threshold Assessment: A positive US (nodule >1 cm) or a significant elevation in biomarkers (e.g., AFP >100 ng/mL) must trigger diagnostic resolution [57].
- Diagnostic Resolution: If screening is positive, proceed to multiphasic CT or dynamic MRI using criteria for confirmation [63][68]D.
High-Risk Populations and Risk Stratification
Surveillance is indicated for patients where the annual incidence of HCC exceeds 1.5% (for cirrhosis) or 0.2% (for non-cirrhotic HBV) [65]D.
- Viral Hepatitis: Chronic HBV remains a leading driver, especially in regions like Egypt where it often presents at advanced stages despite immunization programs [63][71]D. In HCV patients, co-infection with HIV or prior exposure to HBV (HBsAg-negative/HBcAb-positive) significantly increases the risk of progression to HCC [9].
- MASLD: (MASLD) is an increasing cause of HCC. While the annual incidence in non-cirrhotic MASLD is low, the high global prevalence of the condition creates a large absolute burden of cancer, often requiring vigilance in patients with type 2 [16]D.
- Fontan-Associated Liver Disease (FALD): Patients who have undergone Fontan surgery for congenital heart disease are at risk for FALD-HCC, which typically develops at a median age of 32.6 years, approximately 26 years post-surgery [61].
Biomarkers and Advanced Imaging
To overcome the limitations of US, several serum biomarkers and abbreviated imaging protocols are under investigation. The combination of AFP, the lectin-reactive fraction of AFP (AFP-L3), and des-gamma-carboxy prothrombin (DCP) provides a more comprehensive risk profile [57].
| Biomarker | Clinical Threshold for Concern | Rationale |
|---|---|---|
| AFP | >100 ng/mL | Traditional marker; sensitivity is limited when used alone [57]. |
| AFP-L3 | >10% | More specific for HCC than total AFP [57]. |
| DCP | >2 ng/mL | Reflects abnormal prothrombin production in malignant cells [57]. |
| ctDNA | Detectable levels | Bespoke circulating tumor DNA (e.g., Signatera) is emerging for early recurrence detection [64]D. |
Abbreviated gadoxetic acid-enhanced MRI (HBP-AMRI) is being evaluated as a high-sensitivity alternative to US for routine surveillance in cirrhotic patients, potentially offering superior detection of small lesions [59].
Psychosocial and Socioeconomic Factors
Surveillance efficacy is frequently hindered by socioeconomic barriers. Patients residing in areas of persistent poverty or low socioeconomic status (SES) experience lower all-cause and HCC-specific survival [60]. Social risk phenotypes—including lack of insurance, marital status, and distance to screening facilities—strongly correlate with late-stage diagnosis and higher 2-year mortality [62]. Furthermore, false-positive US results can lead to significant psychosocial distress and unnecessary invasive procedures, highlighting the need for more specific screening tools [67]D.
Diagnostic Imaging and LI-RADS Criteria
- ▸HCC can be diagnosed non-invasively in high-risk patients using LI-RADS LR-5 criteria (APHE, washout, capsule, threshold growth) on multiphase CT or MRI.
- ▸The addition of serum biomarkers (AFP, AFP-L3, DCP) to ultrasound surveillance significantly improves early-stage detection rates compared to ultrasound alone.
- ▸Gadoxetate-enhanced MRI provides high sensitivity via the hepatobiliary phase, but washout assessment must be carefully interpreted during the transitional phase to maintain specificity.
Hepatocellular carcinoma (HCC) is unique among solid malignancies because it can be definitively diagnosed in high-risk patients—those with or chronic —using non-invasive imaging criteria alone, often obviating the need for biopsy [72][95]D. This imaging-centric approach relies on the identification of specific vascular patterns that reflect the physiological transition from a portal-supplied regenerative nodule to an arterially-supplied malignant lesion [79]D[81]D.
Diagnostic Criteria and LI-RADS
The Liver Imaging Reporting and Data System (LI-RADS) standardizes the interpretation of multiphase CT and MRI in patients at risk for HCC. The system categorizes observations from LR-1 (definitely benign) to LR-5 (definitely HCC) [80]D[89]D.
Major Imaging Features
To achieve an LR-5 classification, a lesion must demonstrate specific major features on contrast-enhanced imaging [89]D:
- Arterial Phase Hyperenhancement (APHE): Non-peripheral enhancement that is greater than the background liver during the late arterial phase. This reflects the recruitment of unpaired arteries during hepatocarcinogenesis [81]D.
- Non-peripheral Washout: A reduction in enhancement relative to the liver in the portal venous or delayed phases. In gadoxetate-enhanced MRI, extending the washout assessment to the transitional phase (TP) (2–5 minutes post-injection) may increase sensitivity but can reduce specificity if the background liver parenchymal signal is hyperintense [79]D.
- Enhancing Capsule: A peripheral rim of enhancement in the portal venous or delayed phases [89]D.
- Threshold Growth: A size increase of ≥50% within 6 months [89]D.
LR-M Category
Observations that are definitely malignant but do not meet the specific hallmarks of HCC (e.g., rim APHE, peripheral washout, or targetoid appearance) are categorized as LR-M. This category often includes intrahepatic cholangiocarcinoma or combined HCC-cholangiocarcinoma [80]D.
Laboratory Tests and Biomarkers
While imaging is definitive, serum biomarkers are essential for surveillance and risk stratification. The standard approach involves biannual ultrasound (US) combined with alpha-fetoprotein (AFP) [57][65]D.
- AFP Thresholds: An AFP level >100 ng/mL is highly suggestive of HCC in high-risk populations [57].
- Combined Biomarkers: The use of multiple biomarkers—AFP, the lectin-reactive fraction of AFP (AFP-L3 >10%), and des-gamma-carboxy prothrombin (DCP >2 ng/mL, also known as PIVKA-II)—significantly improves the detection of early-stage HCC compared to US alone [57][92]D.
- Scoring Systems: The GALAD score (Gender, Age, AFP-L3, AFP, DCP) and the GAAD algorithm (Gender, Age, AFP, DCP) provide operator-independent, non-invasive risk assessment, particularly useful in patients with metabolic-associated steatotic liver disease where US sensitivity is limited [92]D[93]D.
Imaging Modalities
Multiphase CT and MRI
Multiphase CT is widely used due to its accessibility and speed [94]D. However, MRI offers superior sensitivity, particularly for small lesions (≤20 mm) [95]D[96]D. Abbreviated MRI (AMRI) protocols, which utilize only essential sequences like the hepatobiliary phase (HBP) or diffusion-weighted imaging (DWI), have emerged as cost-effective surveillance alternatives to full contrast-enhanced MRI [95]D.
Contrast-Enhanced Ultrasound (CEUS)
CEUS using perfluorobutane (PFB) allows for real-time assessment of vascularity. PFB is unique as it is taken up by Kupffer cells, providing a "Kupffer phase" that aids in detecting small HCCs [89]D.
Advanced and Emerging Techniques
- Diffusion-Weighted Imaging (DWI): Cirrhosis can alter DWI features; however, apparent diffusion coefficient (ADC) values remain critical for surgical planning and assessing the peri-tumoral microenvironment [83]D.
- PET/CT: While [18F]FDG PET has limited sensitivity for well-differentiated HCC, [68Ga]Ga-FAPI-04 PET/CT shows promise, with significantly higher uptake at tumor margins compared to the center [74].
- Molecular Imaging: Targeted biosynthetic gas vesicles for Glypican-3 (GPC3) expression are being developed for molecular US, potentially allowing for the visualization of specific molecular markers non-invasively [85]D[86]D.
Diagnostic Algorithm
- Step 1: Surveillance. Perform biannual US + AFP in patients with cirrhosis or high-risk HBV [57][65]D.
- Step 2: Initial Positive Screen. If US shows a nodule ≥10 mm or AFP is elevated, proceed to multiphase CT or MRI [57][88]D.
- Step 3: LI-RADS Categorization. Apply LI-RADS criteria.
- LR-5: Confirm HCC; proceed to [80]D.
- LR-4/LR-M: Discuss in multidisciplinary tumor board; consider biopsy or short-interval follow-up [80]D.
- LR-3: Repeat imaging in 3–6 months [89]D.
- Step 4: Preoperative Assessment. Evaluate for microvascular invasion (MVI) using radiomics-clinical nomograms (e.g., integrating Gd-EOB-DTPA MRI features and Ki-67 >20%) or deep learning models to predict prognosis and recurrence risk [73][77][91]D.
| Test/Modality | Finding/Threshold | Sensitivity | Specificity | Timing/Role |
|---|---|---|---|---|
| Ultrasound + AFP | Nodule or AFP >20 ng/mL | Moderate | High | Surveillance (Biannual) [57][65]D |
| Multiphase CT | APHE + Washout | High | Very High | Diagnosis/Staging [94]D |
| Gadoxetate MRI | HBP Hypointensity | Very High | Moderate | Diagnosis/Small Lesions [79]D[96]D |
| PFB CEUS | Late/Mild Washout | High | High | Small HCC (≤20 mm) [89]D |
| GALAD Score | Composite Score | High | High | Risk Stratification [93]D |
Staging and Prognostication Systems
- ▸The BCLC system is the gold standard for HCC staging as it integrates tumor burden, liver function, and performance status to guide treatment.
- ▸Liver function assessment via ALBI grade provides a more objective prognostic measure than the traditional Child-Pugh score by removing subjective clinical variables.
- ▸Multidisciplinary tumor board review is a critical prognostic factor, significantly improving survival rates through optimized staging and treatment selection.
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related mortality globally, accounting for approximately 75% to 85% of primary liver malignancies [98]. Unlike most solid tumors, the prognosis of HCC is uniquely determined by the interplay between tumor burden, the severity of underlying liver dysfunction (typically ), and the patient's functional status [98][106]. Consequently, staging systems must integrate these three domains to provide accurate survival estimates and guide therapeutic selection. A multidisciplinary approach, involving dedicated tumor board reviews, has been shown to significantly increase survival by ensuring patients are staged accurately and receive stage-appropriate interventions [98].
The Barcelona Clinic Liver Cancer (BCLC) System
The BCLC system is the internationally recognized standard for HCC staging because it links disease extent with specific treatment algorithms. It categorizes patients into five stages (0, A, B, C, and D) based on tumor characteristics, Child-Pugh score, and Eastern Cooperative Oncology Group (ECOG) performance status [104][113].
- Very Early (Stage 0) and Early (Stage A): These stages represent patients with preserved liver function and single or small multinodular tumors (up to 3 nodules, each ≤3 cm). These patients are candidates for curative-intent therapies such as surgical resection, , or ablation [100][111]. Perioperative mortality 3-7% is observed in major resections, though minimally invasive techniques like robotic-assisted liver resection (RALR) may offer faster recovery [100][111].
- Intermediate (Stage B): This stage involves multinodular disease beyond the early criteria but with preserved liver function and no vascular invasion. The "Up-to-7" criteria (sum of the largest tumor diameter in cm and the number of tumors) is often used to further stratify this group; those beyond these criteria may benefit more from systemic therapy (e.g., atezolizumab plus bevacizumab) than traditional transarterial chemoembolization (TACE) [104][109].
- Advanced (Stage C): Characterized by portal vein invasion or extrahepatic spread. While systemic therapy is the standard of care, recent evidence suggests that a subset of BCLC-C patients may benefit from surgical resection if deemed resectable by experienced surgeons, or from aggressive "quadruple therapy" combining TACE, hepatic arterial infusion chemotherapy (HAIC), and immunotherapy [101][110][113].
- Terminal (Stage D): Defined by end-stage liver disease (Child-Pugh C) or poor performance status (ECOG >2) not eligible for transplant, where the prognosis is measured in months and focuses on palliation [98].
Assessment of Liver Reserve: Child-Pugh and ALBI
Accurate prognostication requires objective assessment of liver function, as liver failure is a competing cause of death.
- Child-Pugh Score: Traditionally used to assess cirrhosis severity, it incorporates bilirubin, albumin, INR, and the presence of or encephalopathy. However, its reliance on subjective measures (ascites/encephalopathy) can lead to inconsistent staging [104].
- ALBI (Albumin-Bilirubin) Grade: This is an objective alternative that eliminates subjective variables. It is calculated using the formula: (log10 bilirubin [µmol/L] × 0.66) + (albumin [g/L] × -0.085). ALBI is increasingly preferred in clinical trials because it provides a more granular assessment of liver reserve, particularly in patients classified as Child-Pugh A [105].
Prognostic Factors and Recovery Timeline
Survival in HCC is highly dependent on the achievement of a sustained virological response (SVR) in patients with viral etiologies. In HCV-infected patients, DAA-mediated eradication of the virus significantly improves overall survival, even in those with active HCC [112]. For those undergoing curative resection for early-stage disease, functional recovery is generally robust, with approximately 80% walk independently at 6 months post-operatively, though long-term surveillance is mandatory due to high recurrence risks [100][103].
Protocol for Clinical Staging and Prognostication
Step 1 → Tumor Burden Assessment: Perform multiphasic CT or MRI to determine tumor number, size, and presence of macrovascular invasion or extrahepatic spread [98][104]. Step 2 → Liver Function Quantification: Calculate both Child-Pugh score and ALBI grade to determine if the patient has preserved liver reserve (Child-Pugh A/B) or end-stage failure (Child-Pugh C) [104][105]. Step 3 → Performance Status Evaluation: Assess ECOG status (0–4) to determine the patient's ability to tolerate aggressive interventions [113]. Step 4 → Integration: Apply BCLC criteria to determine the stage and primary treatment pathway, followed by multidisciplinary tumor board review [98].
| BCLC Stage | Tumor Burden | Liver Function | Performance Status (ECOG) | Median Survival |
|---|---|---|---|---|
| 0 (Very Early) | Single <2 cm | Child-Pugh A | 0 | >5 years |
| A (Early) | Single or 3 nodules ≤3 cm | Child-Pugh A-B | 0 | >5 years |
| B (Intermediate) | Multinodular, no invasion | Child-Pugh A-B | 0 | ~2.5 years |
| C (Advanced) | Vascular invasion/Spread | Child-Pugh A-B | 1-2 | ~1-1.5 years |
| D (Terminal) | Any | Child-Pugh C | 3-4 | <3 months |
| Factor | Good Prognosis | Poor Prognosis |
|---|---|---|
| Tumor Size | Single <2 cm | Multinodular or >5 cm |
| Vascular Invasion | Absent | Present (Portal vein) |
| Liver Function | ALBI Grade 1 / Child-Pugh A | ALBI Grade 3 / Child-Pugh C |
| Etiology | SVR achieved (HCV) | Active viral replication |
| AFP Levels | <20 ng/mL | >400 ng/mL |
Surgical Management: Resection and Transplantation
- ▸Surgical resection is superior to RFA for very early-stage HCC (≤2 cm) in terms of long-term survival outcomes.
- ▸SBRT (40 Gy/5 fractions) is a safe bridging therapy for transplant candidates, even in those with advanced Child-Pugh B cirrhosis.
- ▸Pre-transplant use of immune checkpoint inhibitors (ICIs) significantly increases the risk of acute allograft rejection and should be managed with caution.
The surgical of hepatocellular carcinoma (HCC) represents the only curative pathway, necessitating a delicate balance between oncological radicality and the preservation of hepatic functional reserve. The choice between partial hepatectomy (PH) and orthotopic liver transplantation (OLT) is dictated by the severity of underlying , the degree of , and the extent of tumor burden [132]D[138]D. While PH offers immediate tumor removal without the need for lifelong immunosuppression, OLT addresses both the malignancy and the underlying pre-malignant cirrhotic environment, significantly reducing the risk of de novo recurrence [119][132]D.
Step 1: Initial Assessment and Resectability Classification
The first priority is to determine if the patient is a candidate for curative-intent surgery. Clinicians must classify patients based on tumor burden and liver function using the Child-Pugh score and the Albumin-Bilirubin (ALBI) grade [131]D[138]D.
- Resectable HCC: Typically defined as a single nodule of any size or multiple nodules confined to one lobe in a patient with Child-Pugh A status and no clinically significant portal (hepatic venous pressure gradient <10 mmHg) [120][131]D.
- Borderline Resectable (BR): Patients are classified as BR1 (macrovascular invasion) or BR2 (high tumor burden). In these cases, systemic chemotherapy (e.g., Atezolizumab plus Bevacizumab) may offer comparable or superior outcomes to immediate surgery [131]D.
- Transplant Candidates: Patients meeting the Milan criteria (one lesion ≤5 cm or up to three lesions ≤3 cm) who have decompensated cirrhosis (Child-Pugh B/C) are primary candidates for OLT [119][132]D.
Step 2: Surgical Resection Protocol
For patients with very early-stage HCC (single tumor ≤2 cm), surgical resection is the first-line treatment of choice, demonstrating superior overall survival (OS) and recurrence-free survival (RFS) compared to percutaneous radiofrequency ablation (RFA) [120][122][123].
- Anatomical vs. Non-Anatomical Resection: Anatomical resection (AR) is preferred to eliminate potential micrometastases within the portal territory. For central tumors (S4/5/8), a parenchymal-sparing approach using the umbilical fissure combined with indocyanine green (ICG) fluorescence imaging can achieve radicality while preserving the left lateral lobe [76]C.
- Margin Management: A wide margin is ideal, but a vascular R1 margin (R1v)—where the tumor is detached from major intrahepatic vessels—is considered oncologically adequate in minimally invasive surgery and does not significantly increase local recurrence rates [124].
- Laparoscopic Approach: Minimally invasive liver surgery (MILS) is recommended for peripheral lesions. It reduces postoperative morbidity and facilitates potential future salvage transplantation [134]D.
Step 3: Bridging and Downstaging for Transplantation
Patients on the OLT waitlist face the risk of tumor progression beyond transplant criteria. Bridging therapies are essential to maintain eligibility, while downstaging aims to bring patients with a higher tumor burden into the Milan criteria [119][129]D.
- Stereotactic Body Radiation Therapy (SBRT): Administer 40 Gy in 5 fractions [119]. SBRT is safe and feasible even in patients with advanced cirrhosis (Child-Pugh B8 or worse) and serves as an effective bridge to OLT [119].
- Conversion Therapy: For initially unresectable HCC, a combination of transarterial chemoembolization (TACE), PD-1 inhibitors (e.g., Pembrolizumab), and Lenvatinib (8 mg or 12 mg daily) can achieve successful conversion to resection in selected patients [127][129]D.
Step 4: Perioperative Optimization and Viral Management
Perioperative care must be tailored to the patient's age and viral status to minimize recurrence and accelerate recovery.
- Enhanced Recovery After Surgery (ERAS): Implement ERAS protocols regardless of age. In patients ≥65 years, ERAS significantly reduces the length of hospital stay and postoperative complications without compromising safety [133]D.
- Antiviral Therapy: For HCV-related HCC, achieving a sustained virological response (SVR) with direct-acting antivirals (DAAs) post-hepatectomy significantly improves OS and RFS [117]. For HBV-related HCC, patients with high preoperative HBsAg levels are at increased risk for recurrence; postoperative antiviral therapy is mandatory to improve RFS [126].
Step 5: Post-Surgical Surveillance and Recurrence Management
Recurrence occurs in approximately 44.5% of patients after curative resection, with the majority being early recurrences (<2 years) driven by microvascular invasion (MVI) [130]D.
- Biomarker Monitoring: Monitor alpha-fetoprotein (AFP) and Mac-2 binding protein glycosylation isomer (M2BPGi). High preoperative M2BPGi levels are strongly associated with post-treatment recurrence (HR 2.15) [121][136]D.
- Genomic Risk: Patients carrying the PNPLA3 I148M variant (rs738409) have a higher risk of recurrence in non-viral HCC and require more intensive surveillance [137]D.
- Management of Recurrence: For small recurrent HCC (≤5 cm), SBRT provides a 3-year local progression-free survival of 84.3%, which is comparable to repeat resection (76.8%) [115].
| Intervention | Indication | Typical Regimen/Dose | Key Consideration | Evidence Level |
|---|---|---|---|---|
| Surgical Resection | Child-Pugh A, single tumor | Anatomical resection | Superior to RFA for tumors ≤3 cm [123] | 2a |
| Liver Transplant | Milan Criteria, Cirrhosis | Orthotopic (OLT) | Definitive treatment for tumor and liver [119] | 2b |
| SBRT (Bridge) | Waitlist maintenance | 40 Gy in 5 fractions | Safe in Child-Pugh B8+ patients [119] | 2b |
| Conversion Therapy | Initially unresectable | TACE + PD-1 + Lenvatinib | Lenvatinib 8-12 mg/day based on weight [129]D | 5 |
| DAA Therapy | HCV-related HCC | Agent-specific (e.g., Sofosbuvir) | SVR improves post-hepatectomy OS [117] | 2b |
Locoregional Therapies: Ablation and Embolization
- ▸Surgical resection provides superior 5-year overall survival compared to RFA for HCC tumors ≤3 cm, although RFA remains a standard for early-stage disease.
- ▸Triple therapy (TACE + Lenvatinib + PD-1 inhibitor) significantly improves survival outcomes in patients with high tumor burden compared to TACE-Lenvatinib doublet therapy.
- ▸The use of a 5% lidocaine patch at the ablation site is an effective evidence-based protocol for reducing acute post-RFA pain and rescue analgesic requirements.
Locoregional therapies (LRTs) represent the cornerstone of for patients with (HCC) who are not candidates for immediate or surgical resection. These interventions are categorized into ablative techniques, which aim for curative-intent destruction of small tumors, and embolic therapies, which provide palliative or downstaging benefits for intermediate-stage disease [146]. The therapeutic landscape is rapidly evolving, with a significant shift toward combining LRTs with systemic agents like (ICIs) and (TKIs) to overcome the limitations of monotherapy [140][146].
Thermal Ablation: RFA and MWA
Thermal ablation, primarily (RFA) and microwave ablation (MWA), is considered a first-line treatment for early-stage HCC (BCLC stage 0 or A). RFA utilizes high-frequency alternating current to induce coagulative necrosis. While highly effective for tumors ≤3 cm, meta-analyses indicate that surgical resection (SR) remains superior in terms of three-year overall survival (HR: 0.73) and five-year overall survival (HR: 0.70) [123]. For "very early stage" HCC (single tumor ≤2 cm), the survival advantage of surgery over RFA is still debated, though some evidence suggests SR provides better recurrence-free survival (RFS) even in these small lesions [120][122].
Protocol: Post-Ablation Pain Management
Effective is critical as standard systemic medications often fail to mitigate acute post-procedural pain [141].
- Step 1: Apply a 5% lidocaine patch to the skin area corresponding to the ablation site immediately post-procedure [141].
- Step 2: Maintain the patch for 12 hours to provide continuous localized analgesia [141].
- Step 3: Monitor Visual Analog Scale (VAS) scores; clinical trials demonstrate that lidocaine patches significantly reduce both pain intensity and the requirement for rescue analgesics compared to placebo [141].
Immunological Impact of Ablation
Local ablation facilitates the release of tumor-associated antigens, potentially priming the immune system [150]D. Recent multi-omics analyses show that RFA induces complex changes in peripheral immune signatures, including alterations in CpG site methylation that correlate with recurrence risk [151]D. Emerging "Multimodal Tumor Thermal Therapy" (MTT), which combines liquid nitrogen freezing followed by radiofrequency heating, has been shown to expand tumor-reactive CX3CR1+GPR56+ T cells, potentially offering more sustained antitumor immunity than RFA alone [150]D.
Transarterial Chemoembolization (TACE)
TACE is the standard of care for intermediate-stage HCC (BCLC B). It involves the delivery of chemotherapeutic agents (e.g., epirubicin) followed by embolic particles to the tumor-feeding arteries, inducing both cytotoxic damage and ischemic necrosis [147][152]D. Despite its widespread use, TACE efficacy is often limited by the pro-angiogenic cascade—specifically the upregulation of hypoxia-inducible factor 1-alpha (HIF-1α)—triggered by the resulting tumor hypoxia [152]D.
TACE Combination Strategies
To counter the hypoxic response and enhance efficacy, TACE is increasingly paired with systemic therapies. The CHANCE2005 trial demonstrated that combining TACE with camrelizumab (200 mg every 3 weeks) and rivoceranib (250 mg daily) is feasible for unresectable HCC [140]. For patients with a high tumor burden (exceeding the up-to-11 criteria), "triple therapy" (TACE + Lenvatinib + PD-1 inhibitor) has shown superior OS and PFS compared to doublet therapy (TACE + Lenvatinib) [154]D.
| Regimen Type | Components | Clinical Context | Evidence Level |
|---|---|---|---|
| Doublet | TACE + Lenvatinib | Intermediate HCC unsuitable for TACE alone [109] | 2b |
| Triple Therapy | TACE + Lenvatinib + PD-1 Inhibitor | High tumor burden or portal vein thrombus [144][154]D | 2b |
| TACE-C-R | TACE + Camrelizumab + Rivoceranib | Unresectable HCC (BCLC A-C) [140] | 1b |
| TCM-TACE | TACE + Traditional Chinese Medicine | Aimed at improving immune function [143] | 2a |
Advanced Embolization and Emerging Technologies
Innovation in embolic agents aims to improve delivery precision and reverse the immunosuppressive tumor microenvironment.
- Absorbable Microspheres: New microspheres co-delivering epirubicin and acriflavine (an HIF-1 inhibitor) can reverse hypoxia and boost immunogenic cell death [152]D.
- Cryogel Microparticles: Photothermal-responsive systems (e.g., SQAP) allow for the controlled release of targeted agents like anlotinib under near-infrared irradiation [149]D.
- Shear-thinning Hydrogels: These biomaterials are being tested in microfluidic models to improve mechanical embolization in complex vascular networks [153]D.
Prognostication and Clinical Considerations
Predicting which patients will benefit from LRT is essential to avoid unnecessary toxicity. The PLANES model (incorporating AFP, tumor size, and vascular invasion) and the GRIm/HCC-GRIm scores (based on LDH, albumin, and neutrophil-to-lymphocyte ratio) serve as validated tools for predicting survival in patients undergoing TACE-based combination therapies [144][148]D.
Clinicians must also monitor for non-hepatic complications. Cardiovascular thrombosis (CVT) is an independent negative prognostic factor for survival post-TACE, particularly as the HCC etiology shifts toward metabolic dysfunction-related steatohepatitis [157]D. Furthermore, the psychological impact of repeated procedures is significant; a high prevalence of psychological crisis has been documented in patients following TACE, necessitating integrated supportive care [158]D.
| Outcome | Radiofrequency Ablation (RFA) | Surgical Resection (SR) | Hazard Ratio (95% CI) |
|---|---|---|---|
| 3-Year Overall Survival | Lower | Higher | 0.73 (0.66–0.80) [123] |
| 5-Year Overall Survival | Lower | Higher | 0.70 (0.63–0.77) [123] |
| Recurrence-Free Survival | Lower | Higher | 0.71 (0.63–0.80) [123] |
| Morbidity | Lower | Higher | N/A |
Radiation Oncology: SBRT and Proton Therapy
- ▸SBRT provides superior local control compared to RFA for recurrent HCC lesions ≤5 cm.
- ▸The addition of SBRT to sorafenib significantly extends overall survival in locally advanced HCC (NRG 1112).
- ▸SBRT is a safe bridging-to-transplant strategy even in patients with Child-Pugh B8/B9 cirrhosis.
External beam radiation therapy (EBRT), specifically stereotactic body radiation therapy (SBRT), has transitioned from a secondary salvage option to a primary treatment modality for hepatocellular carcinoma (HCC) [171]D. This shift is driven by technological advancements that allow for the delivery of ablative doses while sparing healthy liver parenchyma, making it a viable alternative to (RFA) and surgical resection in specific cohorts [115][161].
Step 1: Initial Assessment and Patient Selection
Clinicians must first determine the treatment intent: curative, bridging to transplant, or palliative for macrovascular invasion. SBRT is indicated for solitary lesions ≤5 cm when patients are unsuitable for or refuse surgery/RFA [164]. Unlike thermal ablation, SBRT efficacy is not limited by the "heat-sink" effect near large vessels, making it ideal for perivascular tumors [171]D. For patients awaiting , SBRT serves as an effective bridging therapy; a prospective trial demonstrated that a dose of 40 Gy in 5 fractions is safe even in patients with advanced cirrhosis (Child-Pugh B8 or worse) [119].
Step 2: Simulation and Treatment Planning
Precise motion is mandatory due to respiratory liver excursion. Computed tomography-guided online adaptive radiation therapy (CT-ART) is increasingly utilized to adjust for daily anatomical variations. In a retrospective registry, 77% of fractions required plan adaptation to maintain target coverage while meeting organ-at-risk (OAR) constraints [168]. For tumors in close proximity to the bowel or stomach, clinicians should consider extending the schedule beyond 5 fractions to reduce the risk of hollow viscus toxicity [169].
Step 3: Dose Prescription and Delivery
Standard SBRT protocols typically utilize 40–50 Gy delivered in 5 fractions [164][168].
- For Small HCC (≤5 cm): SBRT has demonstrated superior local progression-free survival (LPFS) compared to RFA (HR 0.45) [161]. Post-hoc analyses also suggest SBRT may provide better 3-year LPFS (84.3%) than surgical resection (76.8%) for recurrent small HCC [115].
- For Locally Advanced HCC: The NRG Oncology/RTOG 1112 phase 3 trial established that SBRT followed by significantly improves overall survival (OS) compared to sorafenib alone (median OS 15.8 vs 12.3 months) [160].
- For Portal Vein Tumor Thrombosis (PVTT): In Vp3/Vp4 PVTT, SBRT combined with and cadonilimab achieved an objective response rate (ORR) of 38.1% [163].
Step 4: Combination Strategies and Overcoming Resistance
SBRT is increasingly used to overcome resistance to immune checkpoint inhibitors (ICIs). In the ReUNION-1 trial, SBRT combined with sintilimab and bevacizumab in ICI-refractory patients achieved a 33.3% ORR in non-irradiated lesions, suggesting a potential abscopal effect [170][174]C. Additionally, combining SBRT with transarterial chemoembolization (TACE) has shown superior local control compared to TACE monotherapy [176].
Step 5: Response Assessment and Follow-up
Post-radiation imaging is complex due to treatment-induced parenchymal changes. Clinicians should utilize the LI-RADS radiation-based treatment response algorithm, which accounts for the variable time (often 3–6 months) required for a complete radiologic response to manifest [172]D.
Particle Therapy (Proton and Carbon Ion)
Proton beam therapy (PBT) offers a unique dosimetric advantage via the Bragg peak, eliminating the exit dose. A large registry and meta-analysis reported a median OS of 53.7 months for particle therapy, with national approval in Japan for tumors ≥4 cm [167].
| Modality | Typical Dose/Fractionation | Primary Indication | Key Evidence | Evidence Level |
|---|---|---|---|---|
| SBRT | 40–50 Gy in 5 fractions | Small HCC (≤5 cm), PVTT, Bridge to LT | Better LPFS than RFA [161] | 1b |
| Proton Therapy | Variable (RBE-weighted) | Large tumors (≥4 cm), Central lesions | Median OS 53.7 months [167] | 2a |
| SBRT + Sorafenib | 27.5–50 Gy in 5 fractions | Locally advanced HCC | OS 15.8 vs 12.3 mo [160] | 1b |
| SBRT + TACE | 40 Gy in 5 fractions | BCLC Stage B | Superior PFS vs TACE alone [176] | 1b |
Systemic Therapy: Immunotherapy and TKIs
- ▸Atezolizumab plus Bevacizumab is the first-line standard of care for unresectable HCC, with low-dose bevacizumab (5–7.5 mg/kg) serving as a potential strategy to mitigate toxicity.
- ▸Viral etiology (HBV/HCV) is a positive predictor of response to immune checkpoint inhibitors, whereas non-viral HCC may derive comparatively less benefit.
- ▸Triple therapy combining locoregional treatments (TACE or HAIC) with ICIs and TKIs is increasingly used for advanced disease with vascular invasion to improve objective response rates.
The of advanced hepatocellular carcinoma (HCC) has undergone a paradigm shift, moving from a decade of tyrosine kinase inhibitor (TKI) monotherapy to a landscape dominated by immune checkpoint inhibitor (ICI) combinations [146][178]. Systemic therapy is indicated for patients with Barcelona Clinic Liver Cancer (BCLC) stage C disease, or stage B disease that has progressed despite locoregional therapy (LRT) [146][182]. Current strategies prioritize dual-agent regimens that combine anti-programmed death-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) antibodies with either anti-angiogenic agents or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies [179][188]D.
Step 1: Initial Assessment and Etiology Stratification
Before initiating systemic therapy, clinicians must confirm Child-Pugh Class A status, as most clinical trial evidence for ICIs is limited to this population [182][186]D. A critical component of the initial assessment is identifying the underlying etiology (HBV, HCV, or non-viral), as this significantly influences the expected benefit from immunotherapy [180].
- Viral HCC (HBV/HCV): Patients with viral-related HCC demonstrate a superior survival benefit from ICI-based therapies compared to those with non-viral HCC [181]. In viral cohorts, the hazard ratio (HR) for overall survival (OS) is consistently lower, suggesting that the viral-induced inflammatory microenvironment may prime the tumor for immune reactivation [180][181].
- Non-viral HCC (NASH/NAFLD): While ICIs remain an option, these patients may derive less benefit due to a distinct tumor immune microenvironment (TIME) characterized by different immune cell infiltration patterns [181][184]D.
- Transplant Candidacy: If a patient is being considered for , ICIs should be used with extreme caution. Pre-transplant exposure to ICIs can disrupt immune homeostasis, significantly increasing the risk of acute T cell-mediated allograft rejection and graft failure [128]D.
Step 2: Selection of First-Line Regimen
The choice of first-line therapy depends on the patient's risk of bleeding (particularly from ) and their underlying comorbidities [191]D.
- Atezolizumab plus Bevacizumab: Administer Atezolizumab 1200 mg IV plus Bevacizumab 15 mg/kg IV every 3 weeks [186]D[191]D. This combination is the preferred first-line standard for unresectable HCC [182]. Bevacizumab's inhibition of VEGF not only reduces angiogenesis but also reverses VEGF-mediated immunosuppression, enhancing ICI efficacy [186]D. For patients at high risk for bevacizumab-related adverse events (AEs), evidence suggests that low-dose bevacizumab (5–7.5 mg/kg) may maintain efficacy while significantly reducing the incidence of grade ≥3 AEs [191]D.
- Durvalumab plus Tremelimumab: This dual ICI regimen (STRIDE protocol) is an alternative for patients with contraindications to anti-angiogenic agents (e.g., high bleeding risk or recent arterial thrombosis) [188]D.
- TKI Monotherapy: Lenvatinib (8 mg for <60 kg; 12 mg for ≥60 kg) or Sorafenib (400 mg BID) remains appropriate for patients with contraindications to immunotherapy or those with Child-Pugh B status in specific clinical contexts [182][185]D.
Step 3: Integration of Locoregional and Triple Therapies
For patients with high tumor burden or macroscopic vascular invasion (MVI), combining systemic therapy with locoregional interventions may improve outcomes [142][148]D.
- TACE-Systemic Combination: Combining (TACE) with ICIs and TKIs/anti-VEGF agents is increasingly utilized [142]. TACE induces immunogenic cell death, releasing tumor antigens that synergize with ICIs [148]D.
- HAIC-Based Triple Therapy: In patients with BCLC stage C and portal vein tumor thrombus (PVTT), Hepatic Arterial Infusion Chemotherapy (HAIC) using the FOLFOX regimen combined with ICIs and TKIs has shown high objective response rates (ORR) [101][129]D. Concurrent administration of HAIC and targeted immunotherapy is generally preferred over sequential administration to maximize synergistic effects [101].
- Multidisciplinary Protocol for MVI: For patients with major vascular invasion, a protocol involving Radiotherapy (RT) after HAIC, followed by maintenance immunotherapy, is an emerging strategy to achieve local control and systemic protection [75].
Step 4: Monitoring and Response Assessment
Response should be evaluated every 6–9 weeks using mRECIST criteria. Traditional biomarkers like alpha-fetoprotein (AFP) should be supplemented with emerging prognostic scores [148]D[186]D.
- GRIm and HCC-GRIm Scores: The Gustave Roussy Immune (GRIm) score (based on albumin, LDH, and neutrophil-to-lymphocyte ratio) and the HCC-specific GRIm score are potent longitudinal indicators of response in patients receiving TACE plus ICIs [148]D.
- Circulating Biomarkers: Elevated levels of Carbonic Anhydrase 9 (CA9) have been identified as a predictive biomarker for poor response to Atezolizumab/Bevacizumab, reflecting a hypoxic and ICI-resistant tumor microenvironment [186]D.
- Radiomics: CT-derived radiomic heterogeneity can help stratify patients likely to respond to combinations like Sintilimab plus Lenvatinib [78]D.
Step 5: Management of Resistance and Second-Line Sequencing
Resistance to first-line TKIs or ICIs often involves metabolic and epigenetic reprogramming [190]D[196]D.
- TKI Resistance: Downregulation of the bile salt export pump (BSEP) leads to intracellular accumulation of glycocholic acid, which activates EGFR signaling and drives TKI resistance [190]D. Restoring BSEP function or using Ursodeoxycholic acid (UDCA) may potentially resensitize tumors to TKIs [190]D. Additionally, malic enzyme 1 (ME1) upregulation contributes to lenvatinib resistance by promoting ferroptosis evasion [196]D.
- Immunotherapy Resistance: Resistance may be mediated by the Nrf2 pathway, which suppresses anti-tumor immunity [197]D. Targeted inhibition of Nrf2 is being investigated to enhance ICI efficacy [197]D.
- Second-Line Options: Following progression on Atezolizumab/Bevacizumab, options include switching to a TKI (Lenvatinib or Cabozantinib) or alternative ICI combinations, though high-quality RCT data for specific sequencing remains an area of active research [178][182].
| Regimen | Mechanism | Dose/Route | Key Considerations | Evidence Level |
|---|---|---|---|---|
| Atezolizumab + Bevacizumab | PD-L1 + VEGF inhibitor | Atez: 1200 mg IV; Bev: 15 mg/kg IV q3w | Preferred 1st-line; requires variceal screening | 1a [182][191]D |
| Durvalumab + Tremelimumab | PD-L1 + CTLA-4 inhibitor | Dur: 1500 mg; Tre: 300 mg (single dose) | STRIDE protocol; avoids VEGF-related bleeding | 2a [188]D |
| Lenvatinib | Multitarget TKI | 8 mg (<60kg) or 12 mg (≥60kg) PO daily | High ORR; preferred if ICIs contraindicated | 2a [182] |
| Sorafenib | Multitarget TKI | 400 mg PO BID | Historical standard; used in Child-Pugh B | 1a [178] |
| Toripalimab + Bevacizumab | PD-1 + VEGF inhibitor | Per trial protocol | Demonstrated superiority over sorafenib in HEPATORCH | 5 [183]D |
Landmark Trials and Key Evidence
- ▸The IMbrave150 trial established atezolizumab plus bevacizumab as the first-line standard of care, demonstrating superior OS and better preservation of quality of life compared to sorafenib.
- ▸The HIMALAYA trial's STRIDE regimen (tremelimumab/durvalumab) provides a long-term survival benefit, with nearly 20% of patients alive at 5 years.
- ▸Lenvatinib remains a potent first-line option, particularly when high objective response rates are prioritized, as demonstrated in the REFLECT trial.
The therapeutic landscape for hepatocellular carcinoma (HCC) has undergone a paradigm shift, transitioning from a decade of tyrosine kinase inhibitor (TKI) monotherapy to a modern era dominated by immune checkpoint inhibitor (ICI) combinations. This evolution is rooted in several pivotal Phase III trials that established the current standards for first-line and subsequent-line systemic therapy.
The Foundation: SHARP and Asia-Pacific Trials
For nearly ten years, sorafenib was the only systemic agent with a proven survival benefit in advanced HCC. The SHARP trial (N=602) randomized patients with Child-Pugh A cirrhosis to sorafenib 400 mg twice daily or placebo [212][217]. Sorafenib demonstrated a median overall survival (OS) of 10.7 months compared to 7.9 months for placebo (HR 0.69; P<0.001) [214]. The Asia-Pacific trial subsequently confirmed these findings in a population with a higher prevalence of hepatitis B virus (HBV), reporting a median OS of 6.5 months for sorafenib versus 4.2 months for placebo [207][214]. These trials established that systemic therapy could improve survival even in the setting of underlying cirrhosis, provided liver function was well-preserved (Child-Pugh A) [216].
The Non-Inferiority Era: REFLECT Trial
The REFLECT trial (N=954) was a global, open-label, non-inferiority study comparing lenvatinib (8 mg or 12 mg daily based on body weight) to sorafenib [205][211]. Lenvatinib met its primary endpoint of non-inferiority for OS, with a median of 13.6 months versus 12.3 months for sorafenib (HR 0.92) [205]. Notably, lenvatinib showed significantly higher objective response rates (ORR 24.1% vs. 9.2% by mRECIST) and longer progression-free survival (PFS) [205][213]. Post-hoc analyses suggested that lenvatinib's efficacy was particularly robust in patients with high baseline alpha-fetoprotein (AFP) levels [215].
The Paradigm Shift: IMbrave150
The IMbrave150 trial (N=501) revolutionized first-line by demonstrating the superiority of the combination of atezolizumab (1200 mg) and bevacizumab (15 mg/kg) every 3 weeks over sorafenib [203][206]. The rationale for this combination lies in the synergistic effect of PD-L1 inhibition and VEGF inhibition; bevacizumab not only inhibits angiogenesis but also reduces VEGF-mediated immunosuppression, enhancing T-cell infiltration [209].
Key Outcomes from IMbrave150:
- Survival: Significant improvement in OS (HR 0.58) and PFS (HR 0.59) compared to sorafenib [204].
- Quality of Life: Patients receiving the combination experienced a longer time to deterioration of health-related quality of life (11.2 months vs. 3.6 months) [204].
- Response: Higher complete response (CR) rates were observed, with some patients maintaining responses even after temporary treatment interruptions [203][206].
Dual Immunotherapy: HIMALAYA Trial
The HIMALAYA trial (N=1171) introduced the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), which utilizes a single high priming dose of the CTLA-4 inhibitor tremelimumab (300 mg) combined with the PD-L1 inhibitor durvalumab (1500 mg every 4 weeks) [198][208]. This design aims to maximize immune activation while minimizing the toxicity associated with chronic CTLA-4 inhibition [210].
Long-term Evidence from HIMALAYA:
- 4-Year OS: The STRIDE regimen maintained a survival benefit with a 4-year OS rate of 25.2% compared to 15.1% for sorafenib [198].
- 5-Year OS: Updated data showed a 5-year OS rate of 19.6% for STRIDE versus 9.4% for sorafenib, representing the longest follow-up for a Phase III IO trial in HCC to date [199].
- Subgroup Efficacy: The benefit was consistent across various etiologies, including the HBV-dominant Asian subgroup (excluding Japan) [202].
Recent Developments and Future Directions
While combinations have become the standard, not all have succeeded. The LEAP-002 trial evaluated lenvatinib plus pembrolizumab versus lenvatinib monotherapy [200]. Although the combination reached a median OS of 21.2 months, it failed to meet the pre-specified statistical significance threshold because the lenvatinib control arm performed better than historical benchmarks (19.0 months) [200].
In the intermediate stage, the LEAP-012 trial demonstrated that adding lenvatinib and pembrolizumab to transarterial chemoembolization (TACE) significantly improved PFS compared to TACE plus placebo, potentially shifting the management of non-metastatic, unresectable HCC [201].
| Trial | Regimen | N | Primary Outcome (OS) | Hazard Ratio (95% CI) |
|---|---|---|---|---|
| SHARP [217] | Sorafenib vs. Placebo | 602 | 10.7 vs. 7.9 mo | 0.69 (0.55–0.87) |
| REFLECT [205] | Lenvatinib vs. Sorafenib | 954 | 13.6 vs. 12.3 mo | 0.92 (0.79–1.06) |
| IMbrave150 [204] | Atezo/Bev vs. Sorafenib | 501 | NR vs. 13.2 mo | 0.58 (0.42–0.79) |
| HIMALAYA [199] | STRIDE vs. Sorafenib | 1171 | 16.4 vs. 13.8 mo | 0.76 (0.63–0.91) |
| LEAP-002 [200] | Len/Pembro vs. Len | 794 | 21.2 vs. 19.0 mo | 0.84 (0.71–0.99)* |
*Did not meet pre-specified statistical significance.
Management of Complications and Cirrhosis
- ▸HCC patients often succumb to liver failure; management must prioritize preserving hepatic reserve through etiologic suppression and metabolic optimization.
- ▸Statins and GLP-1 receptor agonists are emerging as critical adjuncts that reduce the risk of hepatic decompensation and HCC progression.
- ▸Surveillance sensitivity is significantly enhanced by combining biannual ultrasound with a biomarker panel including AFP, AFP-L3, and DCP.
The of (HCC) is inextricably linked to the management of underlying , as liver failure is a frequent cause of mortality independent of tumor progression [218]. Because HCC typically arises within a background of chronic inflammation and architectural remodeling, preserving hepatic reserve is the primary goal of concurrent medical therapy [72][225]D. This requires a dual-track approach: aggressive suppression of the primary etiologic driver (e.g., viral or metabolic) and proactive mitigation of portal hypertensive complications [219][222].
Step 1: Initial Assessment and Severity Classification
Clinicians must first determine the degree of hepatic dysfunction using the Child-Pugh score and MELD-Na to guide treatment eligibility. While imaging-based morphological criteria (e.g., nodularity, portal vein diameter) are central to diagnosis, they lack standardization across guidelines [72]. Therefore, non-invasive tests (NITs) such as the Fibrosis-4 (FIB-4) index, AST to Platelet Ratio Index (APRI), and Enhanced Liver Fibrosis (ELF) score should be used to risk-stratify patients [224][225]D. Patients with F3 fibrosis (severe fibrosis) must be monitored as closely as those with F4 (cirrhosis), as they remain at high risk for decompensation and HCC development [221].
Step 2: Etiologic Suppression and Metabolic Optimization
For patients with chronic hepatitis B (CHB), antiviral therapy is indicated even in those with low-level viremia. Evidence suggests that untreated adults with HBV DNA <20,000 IU/mL and normal ALT still face a risk of progression to cirrhosis and HCC, warranting consideration for expanded treatment thresholds [220]. In patients with chronic hepatitis C (HCV), direct-acting antivirals (DAAs) (e.g., Sofosbuvir/Velpatasvir 400/100 mg PO daily) are essential to achieve sustained virologic response (SVR), which significantly reduces but does not eliminate HCC risk [71]D[228]D. For metabolic dysfunction-associated steatohepatitis (MASH), emerging therapies like Resmetirom and Semaglutide (e.g., 2.4 mg SC weekly) show promise in reversing fibrosis, though they are not yet approved for established MASH-related cirrhosis [218][223].
Step 3: Pharmacologic Mitigation of Decompensation
(e.g., Atorvastatin 20 mg PO daily) should be considered for cirrhotic patients unless contraindicated. Meta-analysis of 25 studies (n=81,992) indicates that statin therapy independently reduces all-cause mortality, hepatic decompensation, and the incidence of new HCC [222]. In patients with coexisting type 2 diabetes and MASLD, GLP-1 receptor agonists or SGLT2 inhibitors (e.g., Empagliflozin 10 mg PO daily) are preferred over DPP-4 inhibitors, as they are associated with a lower incidence of progression to cirrhosis and HCC [223].
Step 4: Enhanced Surveillance and Early Detection
Standard biannual ultrasound (US) has limited sensitivity for early-stage HCC. Sensitivity is improved by combining US with a biomarker panel: Alpha-fetoprotein (AFP) >100 ng/mL, AFP-L3 >10%, and Des-gamma-carboxy prothrombin (DCP) >2 ng/mL [57]. If US is suboptimal due to body habitus or severe cirrhosis, gadoxetic acid-enhanced abbreviated MRI (HBP-AMRI) may be utilized to improve diagnostic performance [59].
Step 5: Bridging Therapy and Liver Reserve Preservation
In patients with advanced cirrhosis (Child-Pugh B8 or worse) who are awaiting liver transplantation, stereotactic body radiation therapy (SBRT) can be safely used as a bridging strategy. A dose of 40 Gy in 5 fractions has demonstrated feasibility and safety without causing significant hepatic decompensation [119]. This allows patients who might otherwise be excluded from liver-directed therapies to maintain transplant eligibility [119].
| Drug Class | Example Agent & Dose | Indication | Clinical Benefit | Evidence Level |
|---|---|---|---|---|
| Statins | Atorvastatin 20 mg PO daily | Cirrhosis (all etiologies) | Reduced mortality and HCC incidence | 2a [222] |
| GLP-1RA | Semaglutide 2.4 mg SC weekly | MASH / T2DM | Reduced progression to cirrhosis | 2b [223] |
| SGLT2i | Empagliflozin 10 mg PO daily | MASH / T2DM | Lower risk of HCC vs DPP-4i | 2b [223] |
| Antivirals | Tenofovir 300 mg PO daily | Chronic HBV | Suppression of HBV DNA; reduced HCC risk | 2a [220] |
| DAAs | Sofosbuvir/Velpatasvir 400/100 mg | Chronic HCV | SVR; reduced risk of decompensation | 5 [71]D |
Future Directions and Emerging Therapies
- ▸Neoadjuvant combinations of PD-1 inhibitors and TKIs (e.g., CARES-009) are being evaluated to reduce recurrence in high-risk resectable HCC.
- ▸GPC3-targeted CAR-T cell therapy and adjuvant RAK cells represent the next frontier in cellular immunotherapy for solid liver tumors.
- ▸The gut-liver axis and the immunosuppressive TME are primary targets for next-generation therapies using nanovaccines and hydrogel delivery systems.
The therapeutic landscape for hepatocellular carcinoma (HCC) is undergoing a paradigm shift from palliative systemic toward curative-intent perioperative strategies and precision . While surgical resection remains the gold standard for early-stage disease, high recurrence rates necessitate the integration of neoadjuvant and adjuvant protocols to improve long-term outcomes [229][230]. Emerging research focuses on overcoming the immunosuppressive tumor microenvironment (TME), leveraging novel cellular targets, and utilizing advanced delivery systems like hydrogels and nanotechnology [237]D[240]D[246]D.
Neoadjuvant and Perioperative Strategies
Neoadjuvant therapy aims to reduce tumor burden, increase the likelihood of R0 resection, and eliminate micrometastases before surgical intervention [229][234]. The CARES-009 trial (Phase 2/3) evaluated the combination of camrelizumab (PD-1 inhibitor) and rivoceranib (VEGFR-2 TKI) in patients with intermediate or high-risk resectable HCC (CNLC stage Ib-IIIa), demonstrating the potential of dual checkpoint and angiogenic blockade in the perioperative setting [229]. Similarly, the PERI-START trial investigated a triple-modality approach combining (TACE), tislelizumab (PD-1 inhibitor), and lenvatinib (TKI) [230].
Standard Neoadjuvant Protocol (Investigational):
- Risk Stratification: Identify high-risk features such as tumor size >5 cm, multinodularity, or macrovascular invasion [229][230].
- Induction Phase: Administer systemic therapy (e.g., PD-1 inhibitor + TKI) or locoregional therapy (e.g., TACE or HAIC) to achieve downstaging [230][234].
- Surgical Assessment: Perform resection following a defined treatment window (e.g., 1–3 weeks post-TACE) [230].
- Adjuvant Maintenance: Continue systemic therapy post-resection to mitigate the risk of late recurrence [229].
Adoptive Cell Therapy and CAR-T
Chimeric Antigen Receptor (CAR) T-cell therapy, successful in hematologic malignancies, is being adapted for HCC by targeting specific surface antigens like Glypican-3 (GPC3) and Alpha-fetoprotein (AFP) [235][241]D[243]D. GPC3 is a particularly attractive target due to its high expression in HCC and minimal expression in healthy liver tissue [241]D. However, the TME poses significant barriers, including limited T-cell infiltration and metabolic competition [236]D[243]D. To counter this, "armored" CAR-T cells are being engineered to secrete cytokines or resist immunosuppressive signals [236]D. Additionally, adjuvant RetroNectin-Activated Killer (RAK) cells, administered at 1 × 10¹⁰ cells per cycle for three quarterly cycles, have shown promise in improving the liver microenvironment and prolonging recurrence-free survival [231].
Immunomodulation and the Tumor Microenvironment
The HCC TME is characterized by chronic inflammation driven by (HBV), metabolic dysfunction, and [238]D[248]D. HBV reprograms the TME through epigenetic dysregulation and metabolic adaptation, promoting immune evasion [238]D. Future therapies aim to remodel this environment using:
- Hydrogel-Based Delivery: Localized, controlled release of ICIs and cytokines to enhance immune cell infiltration while minimizing systemic toxicity [237]D.
- Nanovaccines: Lipid-based or polymeric nanoparticles that encapsulate tumor-associated antigens and adjuvants to induce robust anti-tumor T-cell responses [240]D.
- Microbiome Modulation: Targeting the gut-liver axis, as microbial metabolites like short-chain fatty acids and bile acids significantly influence ICI efficacy [249]D.
Molecular Subtyping and Precision Imaging
Advancements in imaging and molecular biology are enabling more personalized treatment. MRI and CT features are now being linked to specific pathological subtypes, such as the macrotrabecular-massive variant, which is associated with poor prognosis and high AFP levels [244]D. Furthermore, long non-coding RNAs (lncRNAs), specifically RP11-derived lncRNAs, are emerging as sensitive biomarkers for diagnosis and prognosis in serum-based analyses [239]D. In MASH-related HCC, targeting ferroptosis—an iron-dependent form of cell death—represents a novel therapeutic avenue to address the unique metabolic drivers of these tumors [245]D.
| Target/Modality | Mechanism of Action | Clinical Application |
|---|---|---|
| GPC3 | Surface oncofetal protein | CAR-T, NK-cell therapy, and bispecific antibodies [241]D[243]D |
| RAK Cells | Autologous activated T-cells | Adjuvant therapy to prevent post-surgical recurrence [231] |
| Nanovaccines | Antigen/adjuvant delivery | Induction of systemic anti-tumor immunity [240]D |
| Hydrogels | Localized drug release | Remodeling the immunosuppressive TME [237]D |
| Ferroptosis | Iron-dependent cell death | Specifically targeted in MASH-related HCC [245]D |
| LncRNAs | Gene expression regulation | Diagnostic and prognostic serum biomarkers [239]D |
| Trial Name | Regimen | Phase | Target Population |
|---|---|---|---|
| CARES-009 | Camrelizumab + Rivoceranib | 2/3 | Resectable HCC at intermediate/high risk [229] |
| PERI-START | TACE + Tislelizumab + Lenvatinib | 2 | Early-stage, high-risk resectable HCC [230] |
| HAIC Neoadjuvant | Hepatic Artery Infusion Chemotherapy | Meta-analysis | Improving surgical outcomes in resectable HCC [234] |
References
- [1]
Lee SY, Shin HD. “Meta-Analysis of Genetic Variants Associated With HBV Infection Susceptibility and Hepatocellular Carcinoma Risk.” Journal of viral hepatitis (2026). PMID: 41937404 ↗
L2aSR_OBSCited in: Epidemiology and Global Risk Factors - [2]
Yu W, Zhang J, Xia Q. “The clinical utility of serum prealbumin levels as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: a meta-analysis of 2,996 patients.” Frontiers in oncology (2026). PMID: 41907645 ↗
L2aSR_OBSCited in: Epidemiology and Global Risk Factors - [3]
Herrero JI, Agüero F, Manzardo C et al.. “De Novo Cancer in Liver Transplant Patients With Human Immunodeficiency Virus Infection: A Multicenter Nationwide Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41989878 ↗
L2bCOHORTCited in: Epidemiology and Global Risk Factors - [4]
Brandl M, Nurmatov Z, Sattarova G et al.. “Liver cirrhosis and hepatocellular carcinoma attributable to hepatitis B and C in Kyrgyzstan, 2019-2024: a prospective and retrospective study.” The Lancet regional health. Europe (2026). PMID: 41971035 ↗
L2bCOHORTCited in: Epidemiology and Global Risk Factors - [5]
Lei J, Ma H, Chen X et al.. “Low-level HBV viremia independently predicts poor outcomes in patients with intermediate-to-advanced HBV-related hepatocellular carcinoma receiving systemic therapy: a multicenter retrospective study.” Therapeutic advances in medical oncology (2026). PMID: 41970939 ↗
L2bCOHORTCited in: Epidemiology and Global Risk Factors - [6]
Wang Y, Li Y, Yu Y et al.. “Long-term Dynamic Virological Response Patterns and Clinical Outcomes in Hepatitis B Virus-related Cirrhosis: A Real-world 10-year Cohort Study.” Journal of clinical and translational hepatology (2026). PMID: 41970187 ↗
L2bCOHORTCited in: Epidemiology and Global Risk Factors - [7]
Kornerup LS, Kraglund F, Vilstrup H et al.. “Risk and prognosis of HCC in patients with thyroid disease: A nationwide cohort study.” Hepatology communications (2025). PMID: 41961637 ↗
L2bCOHORTCited in: Epidemiology and Global Risk Factors - [8]
Ji J, Zhang Y, Yan L et al.. “Tyrosine kinase inhibitors combined with PD-1 inhibitors reduce peritoneal metastasis risk for patients with ruptured HCC receiving TACE/TAE: a multicenter retrospective study.” World journal of surgical oncology (2026). PMID: 41957798 ↗
L2bCOHORTCited in: Epidemiology and Global Risk Factors - [9]
Al-Shuaili HH, Al-Busafi SA, Al Busafi SS et al.. “Impact of Hepatitis B Exposure and/or HIV Co-Infection on Clinical Outcomes in Chronic Hepatitis C Patients in Oman: An Ambidirectional Cohort Study.” Journal of medical virology (2026). PMID: 41949324 ↗
L2bCOHORTCited in: Epidemiology and Global Risk Factors, Surveillance and Early Detection, Management of Complications and Cirrhosis - [10]
Kakizaki S, Ikegami T, Hatanaka T et al.. “Long-Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study.” Hepatology research : the official journal of the Japan Society of Hepatology (2026). PMID: 41918474 ↗
L2bCOHORTCited in: Epidemiology and Global Risk Factors - [11]
Dai Z, Wong KT, Chow E et al.. “Mass hepatitis C virus screening among persons in custody in Hong Kong: a modelling cost-effectiveness analysis based on a prospective cohort study.” The Lancet regional health. Western Pacific (2026). PMID: 41909163 ↗
L2bCOHORTCited in: Epidemiology and Global Risk Factors - [12]
Zhang R, Zong D, Liu R et al.. “TRMT6-Mediated m1A Modification of CDK9 mRNA Is a Dual-Pronged Pathogenic Driver for HBV-Related Hepatocellular Carcinoma.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 42003777 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors - [13]
Asero C, Franzè MS, Maltese T et al.. “From Cure to Complexity: Post-SVR Liver and Metabolic Trajectories in Diabetic Patients.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41999061 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors - [14]
Ran C, Gao X, Zhou Y et al.. “Critical role of interleukin-33 in pathogenesis and progression of metabolic dysfunction-associated steatotic liver disease.” Frontiers in medicine (2026). PMID: 41987776 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Global Risk Factors - [15]
Carboni G, Concatto NH, Vanceta R et al.. “MRI risk stratification in metabolic dysfunction-associated steatotic liver disease (MASLD): from diffuse liver disease to focal lesions.” Abdominal radiology (New York) (2026). PMID: 41986476 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Global Risk Factors - [16]
Mitten EK, Portincasa P, Baffy G. “Risk Assessment and Prediction of Hepatocellular Carcinoma in Noncirrhotic Metabolic Dysfunction-Associated Steatotic Liver Disease.” International journal of molecular sciences (2026). PMID: 41977422 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Global Risk Factors, Surveillance and Early Detection - [17]
Hefner M, Hia RA, Nguyen T et al.. “Reproducibility and Sex Differences in a STZ-High-Fat Diet Model of MASLD and Early Hepatocarcinogenesis.” International journal of molecular sciences (2026). PMID: 41977383 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors - [18]
Karachaliou GS, Perkins AM, Dorn C et al.. “Association of Statin Use with Reduced Primary Liver Cancer Risk, Independent of Age and Cirrhosis Protection in MASLD.” Cancers (2026). PMID: 41976355 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors - [19]
Choi J, Mitchell G, Nguyen VH et al.. “GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes.” Hepatology communications (2026). PMID: 41974037 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors - [20]
Kim D, Woo BH, Kim SH et al.. “Molecular insights into CRIP1 as an immunometabolic regulator revealed by CRIP1 knockout and single-cell transcriptomics.” Frontiers in immunology (2026). PMID: 41972184 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors - [21]
Yu Z, Gunalan SZ, Tang NSY et al.. “Dynamic Risk Modelling of Hepatocellular Carcinoma.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41968538 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors, Surveillance and Early Detection, Surgical Management: Resection and Transplantation - [22]
Zou J, Dai Y, Yu Y et al.. “Integrated analysis of network pharmacology and multi-omics reveals the mechanisms of Zuogui Jiangtang Qinggan formula ameliorates MASLD via fatty acid metabolic reprogramming.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 41962267 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors - [23]
Kozlitina J, Romeo S, Hobbs HH. “Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment.” Hepatology (Baltimore, Md.) (2026). PMID: 41962050 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors - [24]
Li T, Chen H, Zhao P et al.. “A tale of dual role: HECT‑type E3 ubiquitin ligase mechanisms in liver diseases (Review).” International journal of molecular medicine (2026). PMID: 41952501 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Global Risk Factors - [25]
Van Renne N, Ballet F, Van Hees S et al.. “A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells.” JHEP reports : innovation in hepatology (2026). PMID: 41951276 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors - [26]
Lin Q, Miao G, Wang L et al.. “Clinical and MRI features for differentiating reactive lymphoid hyperplasia from hepatocellular carcinoma in non-cirrhotic chronic HBV patients.” European journal of radiology (2026). PMID: 41950865 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors - [27]
Yuan J, He J, Liu W et al.. “Hepatitis C virus core promotes hepatic cancer stem cell formation via β-catenin-mediated EpCAM upregulation.” Microbiology spectrum (2026). PMID: 41949305 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors - [28]
Martini A, Iavarone M, D'Ambrosio R et al.. “Impact of Hepatocellular Carcinoma on the risk of liver decompensation: a comparative analysis of patients with and without HCC: Role of HCC in liver decompensation.” JHEP reports : innovation in hepatology (2026). PMID: 41942035 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors - [29]
Lin L, Yang S, Zhang J et al.. “GPX2+ tumor cells recruit LGALS1+ B cells via CCL26-CCR3 axis to promote immunosuppression and tumor progression in hepatocellular carcinoma.” Frontiers in immunology (2026). PMID: 41939890 ↗
L5OTHERCited in: Epidemiology and Global Risk Factors - [30]
Hu Z, Tian D, Yang Z et al.. “The mechanisms of GLP-1 receptor agonists in liver diseases: their multifaceted impact on immune response and metabolic regulation.” Frontiers in pharmacology (2026). PMID: 41939830 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Global Risk Factors - [31]
Li YX, Wang RY, Hao YL. “Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) following atezolizumab and bevacizumab treatment for hepatocellular carcinoma.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 41405648 ↗
L2aSR_OBSCited in: Molecular Pathogenesis and Genetics - [32]
Liava C, Venkatesh S, Torbenson MS et al.. “A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series.” Cancer medicine (2026). PMID: 41641648 ↗
L4CASE_REPORTCited in: Molecular Pathogenesis and Genetics - [33]
Haennel Y, Baumert TF, Lupberger J. “Hepatitis D Virus Pathogenesis: A Sense of Complications.” Viruses (2026). PMID: 41902186 ↗
L5REVIEW_NARRATIVECited in: Molecular Pathogenesis and Genetics, Surveillance and Early Detection, Management of Complications and Cirrhosis - [34]
Lin YC, Li WY, Chen YA. “GNMT and Its Regulatory MicroRNAs as Biomarkers and Therapeutic Targets for Metabolic Dysfunction-Associated Fatty Liver Disease and Hepatocellular Carcinoma.” International journal of molecular sciences (2026). PMID: 41828318 ↗
L5REVIEW_NARRATIVECited in: Molecular Pathogenesis and Genetics - [35]
Alawi MMK, Raahim M, Kumar M et al.. “Therapeutic Potential of Silver Nanoparticles in Hepatocellular Carcinoma: From Pathogenesis to Clinical Perspectives.” International journal of nanomedicine (2026). PMID: 41822854 ↗
L5REVIEW_NARRATIVECited in: Molecular Pathogenesis and Genetics - [36]
Chen Q, Feng X, Wang J et al.. “Impact of gut microbiota on hepatocellular carcinoma: Pathogenesis, diagnosis, prognosis, and therapeutic prospective.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41785672 ↗
L5REVIEW_NARRATIVECited in: Molecular Pathogenesis and Genetics - [37]
Xiong S, Hu L, Sun YY et al.. “RNA splicing dysregulation in hepatocellular carcinoma: Molecular mechanisms, therapeutic targets, and intervention strategies-A comprehensive review.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2026). PMID: 41570787 ↗
L5REVIEW_NARRATIVECited in: Molecular Pathogenesis and Genetics - [38]
Lopes XGDCF, Silva Júnior RRD, Fernandes FL et al.. “Epigenetic Mechanisms Involved in Hcv Infection and Human HCC.” International journal of molecular sciences (2025). PMID: 41465470 ↗
L5REVIEW_NARRATIVECited in: Molecular Pathogenesis and Genetics - [39]
Krishnan A, Kadakia KC, Rudnick SR et al.. “Modern Diets, Metabolic Inequity, and Race-Ethnic Disparities: Unraveling the Associations With MASLD and Cancer Risk.” Journal of gastroenterology and hepatology (2026). PMID: 41435869 ↗
L5REVIEW_NARRATIVECited in: Molecular Pathogenesis and Genetics - [40]
Belmer A, Luci C, Gual P. “Role of central and peripheral serotonin in liver physiology and diseases.” Theranostics (2026). PMID: 41424854 ↗
L5REVIEW_NARRATIVECited in: Molecular Pathogenesis and Genetics - [41]
Ştefan AG, Mitrea A, Clenciu D et al.. “MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management-A Narrative Review.” Medicina (Kaunas, Lithuania) (2026). PMID: 41752724 ↗
L5REVIEW_NARRATIVECited in: Molecular Pathogenesis and Genetics - [42]
Machado MV. “Hepatocellular Carcinoma Around the Clock.” Current oncology (Toronto, Ont.) (2026). PMID: 41590352 ↗
L5REVIEW_NARRATIVECited in: Molecular Pathogenesis and Genetics - [43]
Zhou F, Chen T, Tan X et al.. “G2E3 Suppresses the Tumor-Killing Function of CD8+ T Cells in Hepatocellular Carcinoma by Boosting CLCN2 Ubiquitination.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 41999244 ↗
L5OTHERCited in: Molecular Pathogenesis and Genetics - [44]
Sabeel Z, Chen R, Liu Y et al.. “Preclinical Evaluation of Triptophenolide-Induced Apoptosis in Hepatoblastoma (HepG2) and Hepatocellular Carcinoma (HuH7) Cell Lines.” International journal of molecular sciences (2026). PMID: 41977432 ↗
L5OTHERCited in: Molecular Pathogenesis and Genetics - [45]
Ma S, Li Y, Fei T. “Functional CRISPR Screens Define Genetic Drivers for Cancer Transformation and Progression from Non-Cancerous Cells.” International journal of molecular sciences (2026). PMID: 41977403 ↗
L5OTHERCited in: Molecular Pathogenesis and Genetics - [46]
Lin KH, Lin YJ, Hong YB et al.. “Glutamic Acid-Chelated Cobalt Stabilizes G-Quadruplexes and Selectively Suppresses Hepatocellular Carcinoma Growth.” Oncology research (2026). PMID: 41930173 ↗
L5OTHERCited in: Molecular Pathogenesis and Genetics, Systemic Therapy: Immunotherapy and TKIs - [47]
Hu M, Zhang N, Wang YQ et al.. “GNPAT promotes immunosuppression in hepatocellular carcinoma by activating the plasmalogen-PPARγ pathway to drive M2 macrophage polarization.” Frontiers in immunology (2026). PMID: 41816340 ↗
L5OTHERCited in: Molecular Pathogenesis and Genetics - [48]
Zhang S, Zhao Y, Geng L et al.. “DNASE1L3 Mediates Hepatocellular Carcinoma Tumor Growth and Organoid Models via the Wnt/β-Catenin Signaling Pathway.” Oncology research (2026). PMID: 41799507 ↗
L5OTHERCited in: Molecular Pathogenesis and Genetics - [49]
Xiang X, Zhu J, Jiang J et al.. “Unique gut microbiota and metabolomic profiling as biomarker of post-transplant recovery in acute-on-chronic liver failure after liver transplantation.” Applied microbiology and biotechnology (2026). PMID: 41776098 ↗
L5OTHERCited in: Molecular Pathogenesis and Genetics, Surgical Management: Resection and Transplantation - [50]
Gu X, Zhou H, Chen W et al.. “YTHDF1-mediated RNA m1A methylation promotes malignant progression of hepatocellular carcinoma via regulating LRP5/Wnt-β-catenin axis.” Cancer letters (2026). PMID: 41740302 ↗
L5OTHERCited in: Molecular Pathogenesis and Genetics - [51]
Wu YH, Tseng YF, Yang YJ et al.. “Synchronous two-nodule hepatocellular carcinoma without satellite nodules is associated with better survival outcomes compared with satellite-nodule hepatocellular carcinoma.” Journal of clinical pathology (2026). PMID: 41708315 ↗
L5OTHERCited in: Molecular Pathogenesis and Genetics, Surgical Management: Resection and Transplantation - [52]
Zhang MY, Sun RQ, Min Q et al.. “Synergistic antitumor effect of oroxylin A and donafenib in hepatocellular carcinoma through tumor protein p53 signaling pathway activation.” World journal of gastroenterology (2026). PMID: 41695286 ↗
L5OTHERCited in: Molecular Pathogenesis and Genetics - [53]
Stenbäck JB, Ringlander J, Andersson M et al.. “Novel Long-Read Sequencing Method for Characterisation of Hepatitis B Transcripts Show High Expression of Chimeric HBV/Human RNA.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41684309 ↗
L5OTHERCited in: Molecular Pathogenesis and Genetics - [54]
Yao Y, Song D, Li M et al.. “Integrated Single-Cell and Bulk Transcriptome Analysis Reveals the Prognostic Significance and Immune Regulatory Mechanisms of Sialylation in Hepatocellular Carcinoma.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 41661103 ↗
L5OTHERCited in: Molecular Pathogenesis and Genetics - [55]
Cheng CC, Yeh HZ, Sie ZL et al.. “Radiotherapy enhances M1 macrophage immunogenic activity through IFNs induction and stimulation in TP53-wild type tumors.” Cancer immunology, immunotherapy : CII (2026). PMID: 41653234 ↗
L5OTHERCited in: Molecular Pathogenesis and Genetics - [56]
Akkus E, Yaşar HA. “Immune Checkpoint Inhibitor-Based Adjuvant Treatment Versus Surveillance in Curatively Treated Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis.” Journal of gastroenterology and hepatology (2026). PMID: 41827017 ↗
L2aSR_OBSCited in: Surveillance and Early Detection, Surgical Management: Resection and Transplantation, Systemic Therapy: Immunotherapy and TKIs - [57]
Hirode G, Zangneh HF, Cerocchi O et al.. “Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial.” Gastroenterology (2026). PMID: 41556856 ↗
L1bRCTCited in: Surveillance and Early Detection, Diagnostic Imaging and LI-RADS Criteria, Staging and Prognostication Systems, Management of Complications and Cirrhosis - [58]
Hsiehchen D, Singal AG. “Hepatocellular carcinoma: Clinical trials to watch.” Med (New York, N.Y.) (2026). PMID: 41831431 ↗
L2bTRIAL_NONRANDOMCited in: Surveillance and Early Detection, Staging and Prognostication Systems - [59]
Park HJ, Choi J, Kim DW et al.. “Abbreviated gadoxetic acid-enhanced MRI versus ultrasonography for HCC surveillance in high-risk patients: A randomized trial protocol.” Hepatology communications (2025). PMID: 41481895 ↗
L2bTRIAL_NONRANDOMCited in: Surveillance and Early Detection, Staging and Prognostication Systems, Management of Complications and Cirrhosis - [60]
Elsaid MI, Loomans-Kropp HA, Kweon Y et al.. “Impacts of Neighborhood Persistent Poverty and Socioeconomic Status on Hepatocellular Carcinoma Outcomes: A Large Population-Based Cohort Study.” Cancer medicine (2026). PMID: 41844357 ↗
L2bCOHORTCited in: Surveillance and Early Detection - [61]
Kogiso T, Takano S, Ogasawara Y et al.. “Clinical Outcomes of Fontan-Associated Hepatocellular Carcinoma: a Single-Center Retrospective Study.” Journal of gastroenterology and hepatology (2026). PMID: 41669856 ↗
L2bCOHORTCited in: Surveillance and Early Detection - [62]
Nephew LD, Carter A, Varghese N et al.. “Social Risk Phenotypes Are Strongly Associated With Hepatocellular Carcinoma Outcomes: A Statewide Cohort Study Using Latent Class Analysis.” Clinical and translational gastroenterology (2026). PMID: 41537518 ↗
L2bCOHORTCited in: Surveillance and Early Detection - [63]
Barakat EMF, Kohla M, Tawheed A et al.. “Outcomes and Survival of Egyptian Patients With Hepatitis B-Related Hepatocellular Carcinoma: A Multicentre Retrospective Study.” Journal of viral hepatitis (2026). PMID: 41482807 ↗
L2bCOHORTCited in: Surveillance and Early Detection, Locoregional Therapies: Ablation and Embolization - [64]
Abidoye O, Pirozzi A, Okano N et al.. “Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience.” JCO precision oncology (2026). PMID: 41955548 ↗
L5OTHERCited in: Surveillance and Early Detection - [65]
Hunold T, Parikh ND. “Risk-stratified surveillance for hepatocellular carcinoma.” Hepatology communications (2026). PMID: 41921193 ↗
L5REVIEW_NARRATIVECited in: Surveillance and Early Detection, Diagnostic Imaging and LI-RADS Criteria - [66]
Duan Y, Yang M, Li M et al.. “Microbiome and metabolite signatures for cirrhosis to HCC risk stratification: progress, controversies, and gaps.” Frontiers in cellular and infection microbiology (2026). PMID: 41918873 ↗
L5REVIEW_NARRATIVECited in: Surveillance and Early Detection, Management of Complications and Cirrhosis - [67]
Hui S, Le S, Dev A et al.. “Psychosocial impact of false-positive surveillance for hepatocellular carcinoma: a qualitative study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41876867 ↗
L5OTHERCited in: Surveillance and Early Detection, Diagnostic Imaging and LI-RADS Criteria - [68]
Naves GG, Dantas PP, Júnior AEDS et al.. “CT and MRI LI-RADS Treatment Response Assessment 2024: Core Concepts for Clinical Practice.” Radiographics : a review publication of the Radiological Society of North America, Inc (2026). PMID: 41855078 ↗
L5REVIEW_NARRATIVECited in: Surveillance and Early Detection, Diagnostic Imaging and LI-RADS Criteria - [69]
Sheng X, Mi C, Shi G et al.. “Targeting copper death-related long non-coding RNAs: a novel strategy to overcome immunotherapy resistance in liver cancer.” Frontiers in immunology (2026). PMID: 41846915 ↗
L5REVIEW_NARRATIVECited in: Surveillance and Early Detection - [70]
Li Z, Gong Y, Ye L et al.. “The dual roles of natural killer cells in liver immunity and tolerance: Implications for health and disease.” Hepatology communications (2026). PMID: 41824635 ↗
L5REVIEW_NARRATIVECited in: Surveillance and Early Detection - [71]
El-Kassas M, Khalifa R, Kohla M et al.. “Hepatocellular Carcinoma in Egypt in the Post HCV Elimination Era: Changing Aetiology, Surveillance, and Management Pathways.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41823042 ↗
L5REVIEW_NARRATIVECited in: Surveillance and Early Detection, Management of Complications and Cirrhosis - [72]
Lim MC, Quek EJW, Chan TYH et al.. “Systematic Review: Imaging-Based Morphological Criteria for Liver Cirrhosis-A Call to Standardise.” Alimentary pharmacology & therapeutics (2026). PMID: 41882492 ↗
L2aSR_OBSCited in: Diagnostic Imaging and LI-RADS Criteria, Management of Complications and Cirrhosis - [73]
Feng W, Qu B, Han S. “Accuracy of Medical Image-Based Deep Learning for Detecting Microvascular Invasion in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis.” Journal of medical Internet research (2026). PMID: 41814977 ↗
L2aSR_OBSCited in: Diagnostic Imaging and LI-RADS Criteria - [74]
Zhu D, Zhu Y, Zou S et al.. “Radioactive Distribution Patterns of [ 68 Ga]Ga-FAPI-04 in Primary Hepatocellular Carcinoma.” Clinical nuclear medicine (2026). PMID: 41649855 ↗
L2bTRIAL_NONRANDOMCited in: Diagnostic Imaging and LI-RADS Criteria - [75]
Doi Y, Aikata H, Kosaka Y et al.. “Multidisciplinary Treatment With Hepatic Arterial Infusion Chemotherapy, Radiotherapy, and Immunotherapy for Advanced Hepatocellular Carcinoma With Major Vascular Invasion: Prospective Registry Protocol.” JMIR research protocols (2026). PMID: 41915762 ↗
L2bTRIAL_NONRANDOMCited in: Diagnostic Imaging and LI-RADS Criteria, Systemic Therapy: Immunotherapy and TKIs - [76]
Wu P, Erxiding N, Yang J. “Laparoscopic Anatomical S4/5/8+S3v Hepatectomy: Umbilical Fissure Approach Combined with Indocyanine Green Fluorescence Imaging.” Annals of surgical oncology (2026). PMID: 41688835 ↗
L4CASE_REPORTCited in: Diagnostic Imaging and LI-RADS Criteria, Surgical Management: Resection and Transplantation - [77]
Yu H, Kong D, Mo X et al.. “Gd-EOB-DTPA MRI radiomics-clinical nomogram for preoperatively predicting dual-positive Ki-67/MVI status in hepatocellular carcinoma: A retrospective study.” Medicine (2026). PMID: 41790668 ↗
L2bCOHORTCited in: Diagnostic Imaging and LI-RADS Criteria - [78]
Cui Y, Wang L, Li X et al.. “Radiomics and blood biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma.” Frontiers in immunology (2026). PMID: 41972186 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria, Systemic Therapy: Immunotherapy and TKIs - [79]
Cho SH, Jung YJ, Hong SB et al.. “Gadoxetate-enhanced MRI Transitional Phase Parenchymal Signal: Effect on Washout and LI-RADS Diagnostic Performance for Hepatocellular Carcinoma.” Radiology (2026). PMID: 41914861 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [80]
Jung YJ, Kim S, Song IH et al.. “Prognostic Significance of Intraindividual CT and MRI LI-RADS Agreement and Discordance in Hepatocellular Carcinoma.” Radiology. Imaging cancer (2026). PMID: 41891826 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [81]
Liu K, Zheng B, Zhang Y et al.. “Clinical Utility of Deep Learning-based Multiple Arterial Phase MRI in Hepatocellular Carcinoma.” Radiology. Imaging cancer (2026). PMID: 41860367 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [82]
Ou Y, Yan P, Liang T et al.. “Multimodal therapeutic efficacy model for predicting early treatment response to TACE-HAIC combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in unresectable hepatocellular carcinoma.” European journal of radiology (2026). PMID: 41846065 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria, Locoregional Therapies: Ablation and Embolization - [83]
Zhu J, Du Y, Hu Y et al.. “Effects of cirrhosis on 3.0 T MRI DWI features of hepatocellular carcinoma, peri-tumoral sub-zones, and background liver: clinical implications for surgical planning.” European journal of radiology (2026). PMID: 41833232 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [84]
Choi ES, Koo B, Kim S et al.. “MRI-based Risk Scoring System to Predict Early Recurrence after Resection of Solitary Hepatocellular Carcinoma 5 cm or Smaller.” Radiology (2026). PMID: 41805416 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [85]
Liang X, Li L, Wang Y et al.. “A Look Behind the Paper: Glypican-3-targeted US Molecular Imaging of Hepatocellular Carcinoma.” Radiology. Imaging cancer (2026). PMID: 41790019 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [86]
Liang X, Li L, Wang Y et al.. “US Molecular Imaging of Glypican-3 Expression in Hepatocellular Carcinoma Using Targeted Biosynthetic Gas Vesicles.” Radiology. Imaging cancer (2026). PMID: 41790017 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [87]
Huaroc Moquillaza E, Steinhelfer L, Weiss K et al.. “Clinical feasibility of accelerated whole liver water T1 mapping with T2*-compensation.” European radiology experimental (2026). PMID: 41779069 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [88]
Yoon JH, Choi JY, Kim YK et al.. “Diagnostic Performance and Clinical Implications of the "Probable Hepatocellular Carcinoma" Category in the Korean Liver Cancer Association-National Cancer Center Korea Guidelines v2022.” Korean journal of radiology (2026). PMID: 41776851 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [89]
Li Y, Lu S, Mao S et al.. “Contrast-Enhanced US Using Perfluorobutane for Diagnosing Small HCC in High-Risk Patients: Comparison with MRI LI-RADS Version 2018.” Radiology (2026). PMID: 41773972 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [90]
Dong W, Wei Y, Cao C et al.. “Cell membranes-encapsulated gadolinium-doped carbon dots for the efficient photothermal and immunotherapeutic synergistic treatment of hepatocellular carcinoma.” Journal of nanobiotechnology (2026). PMID: 41723470 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [91]
Pan Y, Ye R, Li J et al.. “Impact of Annotation Level on Multisequence MRI Models for Preoperative Microvascular Invasion Prediction in Hepatocellular Carcinoma.” Radiology. Imaging cancer (2026). PMID: 41718534 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [92]
Porta C, Pradelli L, Cirotto G et al.. “Cost-effectiveness of the GAAD algorithm for hepatocellular carcinoma surveillance of patients with compensated cirrhosis: a model-based analysis using Italian real-world data.” Journal of medical economics (2026). PMID: 41701165 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [93]
Prakash HS, Sehrawat A, Swamy AM et al.. “Refining early detection of hepatocellular carcinoma: The promise of the GALAD score.” World journal of gastroenterology (2026). PMID: 41694485 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [94]
Chen Y, Zhang Q, Zhang MY. “Deep learning techniques for using computed tomography imaging for hepatocellular carcinoma diagnosis, treatment and prognosis.” World journal of gastroenterology (2026). PMID: 41693978 ↗
L5REVIEW_NARRATIVECited in: Diagnostic Imaging and LI-RADS Criteria - [95]
Park HJ, Kim SY, Lim YS. “Updates in Abbreviated MRI-Based HCC Surveillance.” Journal of gastroenterology and hepatology (2026). PMID: 41685897 ↗
L5REVIEW_NARRATIVECited in: Diagnostic Imaging and LI-RADS Criteria - [96]
Lewis S, Wildman-Tobriner B, Cuevas J et al.. “Quality of Gadoxetate-enhanced MRI versus US during Hepatocellular Carcinoma Screening in Participants with Cirrhosis.” Radiology (2026). PMID: 41665498 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [97]
Zhang Y, Qian X, Zhou C et al.. “Virtual Multi-Phase Contrast Enhanced Liver MRI Using Deep Learning for Evaluating Hepatocellular Carcinoma.” NMR in biomedicine (2026). PMID: 41629748 ↗
L5OTHERCited in: Diagnostic Imaging and LI-RADS Criteria - [98]
Smith EN, Bashir MR, Fung A et al.. “ACR Appropriateness Criteria® Staging and Follow-Up of Primary Liver Cancer.” Journal of the American College of Radiology : JACR (2025). PMID: 41193053 ↗
L1cGUIDELINECited in: Staging and Prognostication Systems - [99]
Su J, Su Y, Mai R et al.. “Comparative efficacy of combination regimens based on interventional therapy and immune checkpoint inhibitors (ICIs) in patients with intermediate- and advanced-stage hepatocellular carcinoma: a systematic review, meta-analysis, and network meta-analysis.” Cancer immunology, immunotherapy : CII (2026). PMID: 41653198 ↗
L2aSR_OBSCited in: Staging and Prognostication Systems, Locoregional Therapies: Ablation and Embolization - [100]
Khan S, Younas M, Khalid AA et al.. “Evaluating robotic vs. laparoscopic liver resection for BCLC stage 0-I hepatocellular carcinoma: a meta-analysis of propensity score-matched studies on perioperative outcomes.” Journal of robotic surgery (2025). PMID: 41286224 ↗
L2aSR_OBSCited in: Staging and Prognostication Systems - [101]
Li Z, Xiong M, Xiang Y et al.. “Hepatic arterial infusion chemotherapy (HAIC) combined with sequential or concurrent systemic targeted immunotherapy for advanced hepatocellular carcinoma: a single-center retrospective study.” World journal of surgical oncology (2026). PMID: 41749226 ↗
L2bCOHORTCited in: Staging and Prognostication Systems, Systemic Therapy: Immunotherapy and TKIs - [102]
Sanduzzi-Zamparelli M, Matilla A, Lledo JL et al.. “Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).” Alimentary pharmacology & therapeutics (2026). PMID: 41725391 ↗
L2bTRIAL_NONRANDOMCited in: Staging and Prognostication Systems - [103]
Fang Y, Zhang M, Chen J et al.. “Efficacy and safety of adjuvant short-course immune checkpoint inhibitors following TACE combined with MWA in patients with BCLC A-B hepatocellular carcinoma: a single-arm, prospective, phase II study protocol.” BMJ open (2025). PMID: 41469053 ↗
L2bTRIAL_NONRANDOMCited in: Staging and Prognostication Systems, Locoregional Therapies: Ablation and Embolization - [104]
Ueshima K, Tsuchiya K, Yamashita T et al.. “Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.” Liver international : official journal of the International Association for the Study of the Liver (2025). PMID: 41178454 ↗
L2bTRIAL_NONRANDOMCited in: Staging and Prognostication Systems - [105]
Guan MC, Li N, Ding Q et al.. “Survival benefits of different immunotherapies for hepatocellular carcinoma: a meta-analysis highlighting age, gender, etiology, and tumor burden.” Frontiers in immunology (2025). PMID: 41451207 ↗
L2aSR_OBSCited in: Staging and Prognostication Systems - [106]
Niriella MA, Dayananda PM, Ranathunga VS et al.. “Clinical and Epidemiologic Characteristics of Patients with Hepatocellular Carcinoma in South Asia: A Systematic Review and Meta-analysis.” Journal of gastrointestinal cancer (2026). PMID: 41689607 ↗
L2aSR_OBSCited in: Staging and Prognostication Systems, Locoregional Therapies: Ablation and Embolization, Management of Complications and Cirrhosis - [107]
Xin L, Li Z, Zhai Y et al.. “Efficacy and Safety of Intensity-Modulated Radiotherapy Combined With Regorafenib With or Without Immune Checkpoint Inhibitors as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Real-World Cohort Study From a Single Center.” Cancer medicine (2026). PMID: 41964212 ↗
L2bCOHORTCited in: Staging and Prognostication Systems - [108]
Vithayathil M, Manfredi GF, D'Alessio A et al.. “The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study.” The Lancet. Digital health (2026). PMID: 41688234 ↗
L2bCOHORTCited in: Staging and Prognostication Systems - [109]
Taniki N, Ojiro K, Kasuga R et al.. “Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With Unresectable Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Cohort Study.” Cancer medicine (2026). PMID: 41546425 ↗
L2bCOHORTCited in: Staging and Prognostication Systems, Locoregional Therapies: Ablation and Embolization - [110]
Yin L, Li W, Shao W et al.. “TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study.” Frontiers in immunology (2025). PMID: 41357217 ↗
L2bCOHORTCited in: Staging and Prognostication Systems - [111]
Xia F, Liu X, Yan J et al.. “Clinical and economic outcomes of robotic-assisted, laparoscopic, and open liver resection in BCLC 0/A hepatocellular carcinoma: a nationwide cohort study.” International journal of surgery (London, England) (2026). PMID: 41287872 ↗
L2bCOHORTCited in: Staging and Prognostication Systems - [112]
Lee TY, Yang SS, Tsai PC et al.. “Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41274170 ↗
L2bCOHORTCited in: Staging and Prognostication Systems - [113]
Yoon KC, Suh S, Choi Y et al.. “Survival benefit of resectability determined by multiple surgeons in BCLC-C Stage: A single-center cohort study.” Surgical oncology (2026). PMID: 41232139 ↗
L2bCOHORTCited in: Staging and Prognostication Systems - [114]
Tabrizian P, Chan A, Marino R et al.. “The role of immunotherapy prior to liver transplantation in advanced or down-staged HCC - timing of transplants, selection of patients, and hurdles to overcome with immunosuppression.” International journal of surgery (London, England) (2026). PMID: 41186530 ↗
L5REVIEW_NARRATIVECited in: Staging and Prognostication Systems - [115]
Fu Y, Liu S, Chen J et al.. “Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trials.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41833569 ↗
L1bRCTCited in: Surgical Management: Resection and Transplantation, Radiation Oncology: SBRT and Proton Therapy - [116]
Kodali S, Connor AA, Victor DW et al.. “Incidental Combined Hepatocellular-Cholangiocarcinoma in Liver Transplant Recipients: A Matched Cohort Study.” Transplant international : official journal of the European Society for Organ Transplantation (2025). PMID: 41685088 ↗
L2bCOHORTCited in: Surgical Management: Resection and Transplantation - [117]
Li PS, Yang GD, Huang XN et al.. “Impact of sustained virological response on prognosis after hepatectomy for hepatitis C-related hepatocellular carcinoma: a retrospective cohort study.” BMC infectious diseases (2026). PMID: 41593527 ↗
L2bCOHORTCited in: Surgical Management: Resection and Transplantation - [118]
Wang R, Li Y, Zhang X et al.. “Multi-phase CT-based intratumoral and peritumoral radiomics for predicting tertiary lymphoid structures of hepatocellular carcinoma: a multi-center retrospective cohort study.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41435687 ↗
L2bCOHORTCited in: Surgical Management: Resection and Transplantation - [119]
Rahmani R, Minger J, Kaempf A et al.. “Safety and Feasibility of Stereotactic Body Radiation Therapy for Patients With Hepatocellular Carcinoma and Advanced Cirrhosis Awaiting Liver Transplantation: A Prospective Pilot Clinical Trial.” International journal of radiation oncology, biology, physics (2026). PMID: 41443394 ↗
L2bTRIAL_NONRANDOMCited in: Surgical Management: Resection and Transplantation, Radiation Oncology: SBRT and Proton Therapy, Management of Complications and Cirrhosis - [120]
Yen YH, Liu YW, Hung CH et al.. “Survival Outcome Was Better with Liver Resection than with Percutaneous Radiofrequency Ablation in Patients with Very Early-Stage Hepatocellular Carcinoma: A Single-Center Retrospective Study.” Journal of investigative surgery : the official journal of the Academy of Surgical Research (2026). PMID: 41660702 ↗
L2bCOHORTCited in: Surgical Management: Resection and Transplantation, Locoregional Therapies: Ablation and Embolization - [121]
Stephens KR, Wilson M, Xu M et al.. “Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma.” World journal of gastroenterology (2026). PMID: 41693972 ↗
L2aSR_OBSCited in: Surgical Management: Resection and Transplantation - [122]
Viana EF, Falcão Araújo D, Ribeiro TF et al.. “Radiofrequency ablation versus surgical resection as first-line treatment for very early stage hepatocellular carcinoma: a systematic review with meta-analysis.” Surgical oncology (2026). PMID: 41690098 ↗
L2aSR_OBSCited in: Surgical Management: Resection and Transplantation, Locoregional Therapies: Ablation and Embolization - [123]
Dai LA, Sun M, Li T et al.. “Comparison of surgical resection and radiofrequency ablation for the treatment of small hepatocellular carcinoma (≤ 3 cm): an updated meta-analysis.” Systematic reviews (2026). PMID: 41549287 ↗
L2aSR_OBSCited in: Surgical Management: Resection and Transplantation, Locoregional Therapies: Ablation and Embolization - [124]
Procopio F, Memeo R, Del Fabbro D et al.. “Oncological Adequacy of R1 Vascular Margin in Minimally Invasive Liver Surgery for Hepatocellular Carcinoma and Colorectal Liver Metastases: A Meta-analysis.” Annals of surgical oncology (2026). PMID: 41507450 ↗
L2aSR_OBSCited in: Surgical Management: Resection and Transplantation - [125]
Lan TC, Chen J, Yang Z et al.. “Safety and efficacy of liver transplantation for hepatocellular carcinoma with bile duct tumor thrombus: A single-arm, multicenter, prospective study.” Hepatobiliary & pancreatic diseases international : HBPD INT (2026). PMID: 41714230 ↗
L2bTRIAL_NONRANDOMCited in: Surgical Management: Resection and Transplantation - [126]
Xu R, Su Q, Liao X et al.. “A retrospective study of preoperative HBsAg levels predicting recurrence after curative resection in patients with HBV-associated hepatocellular carcinoma.” Medicine (2026). PMID: 41517784 ↗
L2bCOHORTCited in: Surgical Management: Resection and Transplantation - [127]
Wei ZW, Cai JQ. “[The perioperative safety analysis of conversion therapy for liver cancer: a single-center retrospective study].” Zhonghua wai ke za zhi [Chinese journal of surgery] (2026). PMID: 41771522 ↗
L2bCOHORTCited in: Surgical Management: Resection and Transplantation - [128]
Cho HS, Lee SK. “Liver Transplantation Following Immune Checkpoint Inhibitor Therapy: What Do We Need to Know from Clinical and Immunological Perspective?” International journal of molecular sciences (2026). PMID: 41898542 ↗
L5REVIEW_NARRATIVECited in: Surgical Management: Resection and Transplantation, Systemic Therapy: Immunotherapy and TKIs - [129]
Guo B, Yerken S, Luo C et al.. “Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombus.” BJS open (2025). PMID: 41871372 ↗
L5OTHERCited in: Surgical Management: Resection and Transplantation, Locoregional Therapies: Ablation and Embolization, Systemic Therapy: Immunotherapy and TKIs - [130]
Shehta A, Kandil TS, AbouEl-Magd ES et al.. “Patterns and predictors of recurrence after curative liver resection for hepatocellular carcinoma: Insights from a single Egyptian center.” American journal of surgery (2026). PMID: 41855733 ↗
L5OTHERCited in: Surgical Management: Resection and Transplantation - [131]
Komatsu S, Tada T, Ishihara N et al.. “Impact of Borderline Resectable Criteria on Hepatocellular Carcinoma Treatment From the Perspective of Tumor Burden.” World journal of surgery (2026). PMID: 41814915 ↗
L5OTHERCited in: Surgical Management: Resection and Transplantation - [132]
Ferrarese A, Vivian LM, Martino L et al.. “Transplant hepatology: New epidemiology and indications.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 41796485 ↗
L5REVIEW_NARRATIVECited in: Surgical Management: Resection and Transplantation - [133]
Deng H, Tong XQ, Jiang ZA et al.. “Practical Application of ERAS Protocols in Older Adults with Hepatocellular Carcinoma Undergoing Hepatectomy: A Propensity Score Matching Study.” Clinical interventions in aging (2026). PMID: 41726180 ↗
L5OTHERCited in: Surgical Management: Resection and Transplantation - [134]
Feng W, Ye QW, Wang QL et al.. “Predictors of one-year adverse outcomes after laparoscopic resection for hepatocellular carcinoma: Development and validation of an early-warning model.” World journal of gastroenterology (2026). PMID: 41695284 ↗
L5OTHERCited in: Surgical Management: Resection and Transplantation - [135]
Li J, Liang YB, Chen XM et al.. “Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: implications for postoperative recurrence risk.” Frontiers in immunology (2026). PMID: 41685307 ↗
L5OTHERCited in: Surgical Management: Resection and Transplantation - [136]
Takeda Y, Imamura H, Ichida H et al.. “Re-evaluating the diagnostic value of α-fetoprotein for hepatocellular carcinoma in the direct-acting antiviral era.” Cancer (2026). PMID: 41665927 ↗
L5OTHERCited in: Surgical Management: Resection and Transplantation - [137]
Nakayama Y, Takeishi K, Itoh S et al.. “Patatin-Like Phospholipase Domain Containing 3 I148M Variant Affects Hepatocellular Carcinoma Recurrence After Liver Resection.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41637660 ↗
L5OTHERCited in: Surgical Management: Resection and Transplantation - [138]
Demirors B, Kaltenmeier C, Abdullah A et al.. “Traditional clinical predictors outperform ALBI, NLR, and PLR after curative hepatic resection for HCC in a Western cohort.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2026). PMID: 41617570 ↗
L5OTHERCited in: Surgical Management: Resection and Transplantation - [139]
Eng N, Taute E, Dang H et al.. “Identification of high functioning hepatocellular carcinoma transplant centers in the modern allocation system.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2026). PMID: 41577502 ↗
L5OTHERCited in: Surgical Management: Resection and Transplantation - [140]
Zhu HD, Fan WJ, Zhao C et al.. “Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41734362 ↗
L1bRCTCited in: Locoregional Therapies: Ablation and Embolization - [141]
Chen CJ, Chen WY, Lin CY et al.. “The Effects of Lidocaine Patches on Post-Radiofrequency Ablation Pain in Patients With Hepatocellular Carcinoma.” Cancer medicine (2026). PMID: 41692439 ↗
L1bRCTCited in: Locoregional Therapies: Ablation and Embolization - [142]
Chen X, Huang M, Liu R et al.. “Clinical efficacy of immunotherapy in combination of locoregional therapies for advanced hepatocellular carcinoma: a systematic review and meta-analysis.” Frontiers in immunology (2026). PMID: 41836382 ↗
L2aSR_OBSCited in: Locoregional Therapies: Ablation and Embolization, Systemic Therapy: Immunotherapy and TKIs - [143]
Liu X, Wang Z, Lv X et al.. “Immune effect of Traditional Chinese Medicine combined with transcatheter arterial chemoembolization in treatment of liver cancer: a meta-analysis.” BMC cancer (2026). PMID: 41566457 ↗
L2aSR_OBSCited in: Locoregional Therapies: Ablation and Embolization - [144]
Ya H, Wang K, Wu J et al.. “The PLANES model for unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus lenvatinib and PD-1 inhibitors: a multicenter, retrospective study.” Frontiers in immunology (2025). PMID: 41624866 ↗
L2bCOHORTCited in: Locoregional Therapies: Ablation and Embolization - [145]
Jin F, Miao H, Wang Y et al.. “Construction and external validation of a prognostic model for survival in hepatocellular carcinoma patients undergoing transarterial chemoembolization: a multicenter retrospective cohort study.” World journal of surgical oncology (2026). PMID: 41491485 ↗
L2bCOHORTCited in: Locoregional Therapies: Ablation and Embolization - [146]
Son SY, Geevarghese R, Valizadeh N et al.. “Advancing the frontiers of hepatocellular carcinoma treatment: a comprehensive review of past, ongoing, and future clinical trials.” Chinese clinical oncology (2026). PMID: 41797459 ↗
L2bTRIAL_NONRANDOMCited in: Locoregional Therapies: Ablation and Embolization, Systemic Therapy: Immunotherapy and TKIs, Future Directions and Emerging Therapies - [147]
Zhang L, Yuan J, Liu S et al.. “Analysis of survival prognosis and influencing factors in patients with primary liver cancer after D-TACE: a retrospective cohort study.” BMC gastroenterology (2026). PMID: 41491932 ↗
L2bCOHORTCited in: Locoregional Therapies: Ablation and Embolization - [148]
Qin L, Zhu L, Wang Y et al.. “Longitudinal Monitoring of GRIm and HCC-GRIm Scores Reveals Immunologically Relevant Prognostic Indicators in Hepatocellular Carcinoma Undergoing TACE Plus ICIs and Anti-VEGF Antibodies/TKIs.” Cancer medicine (2026). PMID: 41992524 ↗
L5OTHERCited in: Locoregional Therapies: Ablation and Embolization, Systemic Therapy: Immunotherapy and TKIs - [149]
Zhao Y, Liu Y, Shan J et al.. “A trimodal combination therapy utilizing cryogel microparticles for hepatocellular carcinoma.” Colloids and surfaces. B, Biointerfaces (2026). PMID: 41825284 ↗
L5OTHERCited in: Locoregional Therapies: Ablation and Embolization - [150]
Wang S, Wang Y, Zhang Y et al.. “Multimodal tumor thermal therapy enhances antitumor immunity by expanding tumor-reactive CX3CR1⁺GPR56⁺ T cells in hepatocellular carcinoma.” Theranostics (2026). PMID: 41799205 ↗
L5OTHERCited in: Locoregional Therapies: Ablation and Embolization - [151]
Li K, Shi W, Li Y et al.. “Dynamics of peripheral immune signature identified by multi-omics and its impact on recurrence after radiofrequency ablation of hepatocellular carcinoma.” Frontiers in immunology (2026). PMID: 41798944 ↗
L5OTHERCited in: Locoregional Therapies: Ablation and Embolization - [152]
Guo J, Huang J, Wang Y et al.. “Absorbable microspheres co-delivering HIF-1α inhibitor augment transarterial chemoembolization by reversing tumor hypoxia and immunosuppression.” Acta biomaterialia (2026). PMID: 41796928 ↗
L5OTHERCited in: Locoregional Therapies: Ablation and Embolization - [153]
Jeon K, Kim U, Azzi S et al.. “Bead bed microfluidic device for testing mechanical embolization of shear-thinning hydrogels.” Acta biomaterialia (2026). PMID: 41796923 ↗
L5OTHERCited in: Locoregional Therapies: Ablation and Embolization - [154]
Li Z, Wu H, Xu R et al.. “Retrospective analysis of transarterial chemoembolization or hepatic arterial infusion chemotherapy combined with lenvatinib with or without PD-1 inhibitor as first-line therapy for unresectable hepatocellular carcinoma with high tumor burden: a propensity score-matched study.” Frontiers in immunology (2026). PMID: 41777890 ↗
L5OTHERCited in: Locoregional Therapies: Ablation and Embolization - [155]
Klubien J, Knøfler LA, Larsen PN et al.. “Nationwide study on survival and recurrence of hepatocellular carcinoma after ablation as first treatment.” Surgical oncology (2026). PMID: 41764872 ↗
L5OTHERCited in: Locoregional Therapies: Ablation and Embolization - [156]
Ya H, Wang K, Qin H et al.. “Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD-1 Inhibitor Plus TKIs in Combination of TACE for uHCC.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41696936 ↗
L5OTHERCited in: Locoregional Therapies: Ablation and Embolization - [157]
Fujita K, Takuma K, Nakahara M et al.. “The Clinical Impact of Cardiovascular Thrombosis on Overall Survival in Patients With Hepatocellular Carcinoma After Transarterial Chemoembolization.” Cancer medicine (2026). PMID: 41656171 ↗
L5OTHERCited in: Locoregional Therapies: Ablation and Embolization - [158]
Zhang S, Han T. “Psychological crisis in patients with primary liver cancer after transarterial chemoembolization: epidemiological characteristics and associated factors.” World journal of surgical oncology (2026). PMID: 41630011 ↗
L5OTHERCited in: Locoregional Therapies: Ablation and Embolization - [159]
Tang L, Que K, Lan Y et al.. “Prognostic value of functional MRI and liver function synergy in hepatocellular carcinoma patients receiving combined locoregional-systemic therapy: A multicenter scoring model.” European journal of radiology (2026). PMID: 41621377 ↗
L5OTHERCited in: Locoregional Therapies: Ablation and Embolization - [160]
Dawson LA, Winter KA, Knox JJ et al.. “Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.” JAMA oncology (2025). PMID: 39699905 ↗
L1bRCTCited in: Radiation Oncology: SBRT and Proton Therapy - [161]
Xi M, Yang Z, Hu L et al.. “Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 39693584 ↗
L1bRCTCited in: Radiation Oncology: SBRT and Proton Therapy - [162]
Hsu SJ, Chao YC, Wang SW et al.. “Stereotactic Body Radiation Therapy With Continued First-Line PD-1 Inhibitor-based Therapy as a Resistance-Overcoming Strategy in Oligoprogressive Hepatocellular Carcinoma: A Prospective Phase 2 Clinical Study.” International journal of radiation oncology, biology, physics (2026). PMID: 41520893 ↗
L2bTRIAL_NONRANDOMCited in: Radiation Oncology: SBRT and Proton Therapy - [163]
Mo N, Hu K, Zeng Z et al.. “Stereotactic body radiation therapy combined with cadonilimab and lenvatinib in the treatment of hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombus: a prospective, multicenter, single-arm, phase II clinical trial.” Frontiers in immunology (2025). PMID: 41293180 ↗
L2bTRIAL_NONRANDOMCited in: Radiation Oncology: SBRT and Proton Therapy - [164]
Sanuki N, Kimura T, Takeda A et al.. “Final Results of a Multicenter Prospective Study of Stereotactic Body Radiation Therapy for Previously Untreated Solitary Primary Hepatocellular Carcinoma (The STRSPH Study).” International journal of radiation oncology, biology, physics (2025). PMID: 39706374 ↗
L2bTRIAL_NONRANDOMCited in: Radiation Oncology: SBRT and Proton Therapy - [165]
Komiyama S, Takeda A, Tateishi Y et al.. “Comparison of stereotactic body radiotherapy and transcatheter arterial chemoembolization for hepatocellular carcinoma: Systematic review and meta-analysis.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2025). PMID: 39515381 ↗
L2aSR_OBSCited in: Radiation Oncology: SBRT and Proton Therapy - [166]
Abe T, Iwanaga M, Igari M et al.. “Stereotactic body radiotherapy with CyberKnife for liver-confined hepatocellular carcinoma: systematic review and meta-analysis.” Journal of radiation research (2025). PMID: 40702656 ↗
L2aSR_OBSCited in: Radiation Oncology: SBRT and Proton Therapy - [167]
Mizumoto M, Shibuya K, Terashima K et al.. “Prospective Registry and Meta-Analysis of Particle Therapy for Hepatocellular Carcinoma: Clinical Outcomes and Real-World Impact.” Cancer medicine (2026). PMID: 41717812 ↗
L2aSR_OBSCited in: Radiation Oncology: SBRT and Proton Therapy - [168]
Lukez A, Zhang L, Horwitz EM et al.. “Computed Tomography-Guided Online Adaptive Stereotactic Body Radiation Therapy for Liver Tumors: A Retrospective Study.” International journal of radiation oncology, biology, physics (2025). PMID: 40189074 ↗
L2bCOHORTCited in: Radiation Oncology: SBRT and Proton Therapy - [169]
Renan A, Bruand M, Jolnerovski M et al.. “Local control and recurrence patterns after stereotactic irradiation delivered in more than 4 fractions for hepatocellular carcinomas and liver metastases: a retrospective study.” Radiation oncology (London, England) (2025). PMID: 39915761 ↗
L2bCOHORTCited in: Radiation Oncology: SBRT and Proton Therapy - [170]
Tang J, Yang Y, Liu D et al.. “Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial.” Nature communications (2025). PMID: 41413036 ↗
L2bTRIAL_NONRANDOMCited in: Radiation Oncology: SBRT and Proton Therapy - [171]
Dudzinski SO, Newman NB, McIntyre J et al.. “Emerging evidence-based role for external-beam radiation therapy in hepatocellular carcinoma.” The lancet. Gastroenterology & hepatology (2025). PMID: 39993402 ↗
L5REVIEW_NARRATIVECited in: Radiation Oncology: SBRT and Proton Therapy - [172]
Harmath C, Fung A, Aslam A et al.. “LI-RADS radiation-based treatment response algorithm for HCC: what to know and how to use it.” Abdominal radiology (New York) (2025). PMID: 39424663 ↗
L5REVIEW_NARRATIVECited in: Radiation Oncology: SBRT and Proton Therapy - [173]
Gholami B, Afrasiabi A, Moon AM et al.. “Safety of Combination TARE and SBRT in Hepatocellular Carcinoma: A Review of Literature & Single-Center Case Series.” Current oncology (Toronto, Ont.) (2025). PMID: 41002557 ↗
L4CASE_REPORTCited in: Radiation Oncology: SBRT and Proton Therapy - [174]
Shu P, Wang F, Wang X. “Case Report: Abscopal effect in a patient with refractory metastatic hepatocellular carcinoma treated with stereotactic body radiotherapy and PD-1 inhibitor.” Frontiers in immunology (2025). PMID: 40386774 ↗
L4CASE_REPORTCited in: Radiation Oncology: SBRT and Proton Therapy - [175]
Huesa-Berral C, Terry JF, Kunz L et al.. “Sequencing microsphere selective internal radiotherapy after external beam radiotherapy for hepatocellular carcinoma: proof of concept of a synergistic combination.” The British journal of radiology (2025). PMID: 39418205 ↗
L4CASE_REPORTCited in: Radiation Oncology: SBRT and Proton Therapy - [176]
Saad E, Abdulla M, Nassef A et al.. “Comparison between Trans-Arterial Chemoembolization Followed by Stereotactic Body Radiation Therapy and Trans-Arterial Chemoembolization Alone in BCLC Stage B Hepatocellular Carcinoma: A Pilot Study.” Asian Pacific journal of cancer prevention : APJCP (2024). PMID: 39342585 ↗
L1bRCTCited in: Radiation Oncology: SBRT and Proton Therapy - [177]
Marino R, Hassan AT, Fagenson A et al.. “Liver transplantation for hepatocellular carcinoma following immunotherapy.” Current opinion in organ transplantation (2025). PMID: 40326429 ↗
L5REVIEW_NARRATIVECited in: Radiation Oncology: SBRT and Proton Therapy - [178]
Luo J, Li Z, Ge J et al.. “Exploring the optimal regimen in advanced hepatocellular carcinoma: a protocol of individual patient data network meta-analysis of randomized controlled trials.” Frontiers in immunology (2026). PMID: 41988192 ↗
L1aSR_MA_RCTCited in: Systemic Therapy: Immunotherapy and TKIs - [179]
Wang X, Wang S, Lu J et al.. “Lenvatinib Versus Bevacizumab in Combination With Anti-PD-1/PD-L1 Therapy for uHCC: A Meta-Analysis of East Asian Studies.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 42003041 ↗
L2aSR_OBSCited in: Systemic Therapy: Immunotherapy and TKIs - [180]
Petrelli F, Colombo S, Dottorini L et al.. “Viral hepatitis and immunotherapy outcome in advanced hepatocellular carcinoma: A comprehensive umbrella review of 15 meta-analyses.” Critical reviews in oncology/hematology (2026). PMID: 41794163 ↗
L2aSR_OBSCited in: Systemic Therapy: Immunotherapy and TKIs - [181]
Li Y, Tan X, Fang S et al.. “Differential Efficacy of Immunotherapy for Hepatocellular Carcinoma by Aetiology: A Systematic Review and Meta-Analysis.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2026). PMID: 41764966 ↗
L2aSR_OBSCited in: Systemic Therapy: Immunotherapy and TKIs - [182]
Remitha NPSI, Sasmana IGAP, Kusuma IKWA et al.. “A Network Meta-Analysis Comparing the Efficacy of Lenvatinib, Atezolizumab plus Bevacizumab, and Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma.” Asian Pacific journal of cancer prevention : APJCP (2026). PMID: 41945955 ↗
L2aSR_OBSCited in: Systemic Therapy: Immunotherapy and TKIs - [183]
Wu C, Wei T, Ye X et al.. “Cost-effectiveness analysis of toripalimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.” Frontiers in public health (2026). PMID: 41982889 ↗
L5OTHERCited in: Systemic Therapy: Immunotherapy and TKIs - [184]
Mo Y, Du Z, Liu M. “SLC25A39 Upregulation Is Associated with DNA Methylation, Immune Cell Infiltration, and Poor Prognosis in Hepatocellular Carcinoma.” International journal of molecular sciences (2026). PMID: 41977283 ↗
L5OTHERCited in: Systemic Therapy: Immunotherapy and TKIs - [185]
Fan TC, Hung TH, Yeh CT et al.. “Targeting ST3GAL1 to downregulate ligands for the glycoimmune checkpoint Siglec-7 and reverse immune escape in hepatocellular carcinoma.” Cancer immunology, immunotherapy : CII (2026). PMID: 41961075 ↗
L5OTHERCited in: Systemic Therapy: Immunotherapy and TKIs - [186]
Sato Y, Kodama T, Maesaka K et al.. “Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.” Journal for immunotherapy of cancer (2026). PMID: 41956541 ↗
L5OTHERCited in: Systemic Therapy: Immunotherapy and TKIs - [187]
Dalbeni A, Vicardi M, Natola LA et al.. “The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and Diabetes.” Oncology research (2026). PMID: 41930153 ↗
L5OTHERCited in: Systemic Therapy: Immunotherapy and TKIs - [188]
Nishio A, Kodama T, Daiku K et al.. “Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.” Journal for immunotherapy of cancer (2026). PMID: 41912268 ↗
L5OTHERCited in: Systemic Therapy: Immunotherapy and TKIs - [189]
Liu H, Chen S, Cao M et al.. “The Yin and Yang of tertiary lymphoid structures in primary liver cancer.” Cancer letters (2026). PMID: 41905709 ↗
L5REVIEW_NARRATIVECited in: Systemic Therapy: Immunotherapy and TKIs - [190]
Wu Z, Wang Y, Yu B et al.. “Potentiating BSEP-mediated bile acid efflux reverses first-line tyrosine kinase inhibitor resistance in hepatocellular carcinoma.” Cancer letters (2026). PMID: 41903671 ↗
L5OTHERCited in: Systemic Therapy: Immunotherapy and TKIs - [191]
Lin PT, Teng W, Hsieh YC et al.. “Low-Dose Bevacizumab Maintains Efficacy With Reduced Adverse Events in Liver Cancer.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41902586 ↗
L5OTHERCited in: Systemic Therapy: Immunotherapy and TKIs - [192]
Lin CI, Chiu YW, Yen MS et al.. “Liver-directed AAV-IL-10 therapy enhances CD8+ T cell-mediated immunity against hepatocellular carcinoma.” Journal for immunotherapy of cancer (2026). PMID: 41895716 ↗
L5OTHERCited in: Systemic Therapy: Immunotherapy and TKIs - [193]
Li JR, Pan LX, Su JY et al.. “Construction of TLS-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.” Hepatology communications (2026). PMID: 41894176 ↗
L5OTHERCited in: Systemic Therapy: Immunotherapy and TKIs - [194]
Zhou Z, Xu X. “Extracellular matrix stiffness in hepatocellular carcinoma: mechanisms and targeted therapeutic strategies.” Frontiers in immunology (2026). PMID: 41890723 ↗
L5REVIEW_NARRATIVECited in: Systemic Therapy: Immunotherapy and TKIs - [195]
Yu Y, Zou S, Fan J et al.. “MMP14 is a safe target of CAR-T therapy against liver cancer and metastasis.” Journal of translational medicine (2026). PMID: 41888815 ↗
L5OTHERCited in: Systemic Therapy: Immunotherapy and TKIs - [196]
Wu D, Xu H, Guo Y et al.. “Malic enzyme 1 contributes to tumorigenesis and lenvatinib resistance in hepatocellular carcinoma via FSP1-dependent ferroptosis evasion.” Cell death & disease (2026). PMID: 41881958 ↗
L5OTHERCited in: Systemic Therapy: Immunotherapy and TKIs - [197]
Zhu Y, Liu M, Fan X et al.. “Targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma.” Journal for immunotherapy of cancer (2026). PMID: 41876134 ↗
L5OTHERCited in: Systemic Therapy: Immunotherapy and TKIs - [198]
Sangro B, Chan SL, Kelley RK et al.. “Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38382875 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [199]
Rimassa L, Chan SL, Sangro B et al.. “Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.” Journal of hepatology (2025). PMID: 40222621 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [200]
Llovet JM, Kudo M, Merle P et al.. “Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.” The Lancet. Oncology (2023). PMID: 38039993 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [201]
Kudo M, Ren Z, Guo Y et al.. “Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.” Lancet (London, England) (2025). PMID: 39798578 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [202]
Lau G, Abou-Alfa GK, Cheng AL et al.. “Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.” Journal of hepatology (2025). PMID: 39089633 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [203]
Xu XQ, Li WM, Shi LC et al.. “Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis.” The oncologist (2025). PMID: 40891895 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [204]
Galle PR, Finn RS, Qin S et al.. “Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.” The Lancet. Oncology (2021). PMID: 34051880 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [205]
Yamashita T, Kudo M, Ikeda K et al.. “REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.” Journal of gastroenterology (2020). PMID: 31720835 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [206]
Salem R, Li D, Sommer N et al.. “Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.” Cancer medicine (2021). PMID: 34189869 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [207]
Cheng AL, Kang YK, Chen Z et al.. “Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.” The Lancet. Oncology (2009). PMID: 19095497 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [208]
Sangro B, Galle PR, Kelley RK et al.. “Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38805668 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [209]
Hattenhauer T, Mispelbaum R, Heine A et al.. “On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic information.” Frontiers in immunology (2025). PMID: 41142780 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [210]
Lau G, Sangro B, Cheng AL et al.. “Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.” Hepatology (Baltimore, Md.) (2026). PMID: 40384092 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [211]
Vogel A, Qin S, Kudo M et al.. “Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.” The lancet. Gastroenterology & hepatology (2021). PMID: 34087115 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [212]
Llovet JM, Peña CE, Lathia CD et al.. “Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22374331 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [213]
Finn RS, Kudo M, Cheng AL et al.. “Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34108184 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [214]
Bruix J, Cheng AL, Meinhardt G et al.. “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.” Journal of hepatology (2017). PMID: 28687477 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [215]
Briggs A, Daniele B, Dick K et al.. “Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma.” British journal of cancer (2020). PMID: 32265508 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [216]
Raoul JL, Bruix J, Greten TF et al.. “Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.” Journal of hepatology (2012). PMID: 22245896 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [217]
Bruix J, Raoul JL, Sherman M et al.. “Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.” Journal of hepatology (2012). PMID: 22727733 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [218]
Zhang X, Wong VW. “MASH and liver fibrosis: Clinical trials to watch.” Med (New York, N.Y.) (2026). PMID: 41966712 ↗
L2bTRIAL_NONRANDOMCited in: Management of Complications and Cirrhosis - [219]
Hagström H, Hellmund C, Lazarus JV et al.. “Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41902599 ↗
L2aSR_OBSCited in: Management of Complications and Cirrhosis - [220]
Yucuma D, Rakover A, Warsop ZI et al.. “Natural history of chronic hepatitis B in untreated adults without cirrhosis according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis.” The lancet. Gastroenterology & hepatology (2026). PMID: 41839199 ↗
L2aSR_OBSCited in: Management of Complications and Cirrhosis - [221]
Barrett R, Archer A, Cathcart J et al.. “Progression to Decompensation of Severe Fibrosis Compared to Cirrhosis in MASLD: A Systematic Review and Meta-Analysis.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41546486 ↗
L2aSR_OBSCited in: Management of Complications and Cirrhosis - [222]
Moraes BF, Leite GAPD, Silveira IB et al.. “Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta-Analysis.” Alimentary pharmacology & therapeutics (2026). PMID: 41518144 ↗
L2aSR_OBSCited in: Management of Complications and Cirrhosis - [223]
Sarker J, Okpara E, De Los Santos B et al.. “Comparative effectiveness of GLP-1 receptor agonists, SGLT2 inhibitors and DPP-4 inhibitors on liver outcomes in metabolic dysfunction-associated steatotic liver disease: A retrospective cohort study.” Diabetes, obesity & metabolism (2026). PMID: 41560595 ↗
L2bCOHORTCited in: Management of Complications and Cirrhosis - [224]
Hill TA, West J, Morling JR et al.. “Identifying subjects at risk of liver cirrhosis via a range of thresholds for common fibrosis markers: A Welsh general population-based cohort study.” Journal of internal medicine (2026). PMID: 41496649 ↗
L2bCOHORTCited in: Management of Complications and Cirrhosis - [225]
Neureiter D, Kiesslich T, Ocker M. “Translating Fibrosis to Malignancy: Biomarkers and Therapeutic Opportunities in Liver Fibrosis and Hepatocellular Carcinoma.” Medical sciences (Basel, Switzerland) (2026). PMID: 41892825 ↗
L5REVIEW_NARRATIVECited in: Management of Complications and Cirrhosis - [226]
Sohn EJ, Oh SO. “Mechanisms of Action and Biomarker Potential of ncRNAs in Hepatocellular Carcinoma and Liver Fibrosis: A Review.” Analytical cellular pathology (Amsterdam) (2026). PMID: 41810934 ↗
L5REVIEW_NARRATIVECited in: Management of Complications and Cirrhosis - [227]
Yang Y, He L, Yang W et al.. “Hydroxy Safflower Yellow A: A Natural Compound from Carthamus tinctorius L. with Potent Activity Against Liver Fibrosis and Cancer.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 41764836 ↗
L5REVIEW_NARRATIVECited in: Management of Complications and Cirrhosis - [228]
Wan KR, Qian C, Liu LM. “Mechanism of hepatitis C virus-mediated development and progression of liver cirrhosis and hepatocellular carcinoma.” World journal of gastroenterology (2026). PMID: 41694486 ↗
L5REVIEW_NARRATIVECited in: Management of Complications and Cirrhosis - [229]
Wang Z, Fan J, Zhou S et al.. “Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.” Lancet (London, England) (2025). PMID: 41125112 ↗
L1bRCTCited in: Future Directions and Emerging Therapies - [230]
Kong D, Tang Y, Zhou Y et al.. “PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma.” Future oncology (London, England) (2025). PMID: 41118318 ↗
L2bTRIAL_NONRANDOMCited in: Future Directions and Emerging Therapies - [231]
Wang Y, Xu J, Zhang L et al.. “Prolonged recurrence-free survival by autologous rectronectin-activated killer (RAK) cells in resected high-risk hepatocellular carcinoma: an experimental single-arm phase II trial (pilot study).” International journal of surgery (London, England) (2025). PMID: 40440678 ↗
L2bTRIAL_NONRANDOMCited in: Future Directions and Emerging Therapies - [232]
Zhu W, Fan C, Zhao Y et al.. “Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets.” Hepatology international (2025). PMID: 40156659 ↗
L2bTRIAL_NONRANDOMCited in: Future Directions and Emerging Therapies - [233]
Zhou Y, Yao MH, Ma J et al.. “Efficacy and safety of immune checkpoint inhibitors in hepatocellular carcinoma: a comprehensive umbrella review of meta-analyses.” International journal of surgery (London, England) (2026). PMID: 41208807 ↗
L2aSR_OBSCited in: Future Directions and Emerging Therapies - [234]
Shang ZK, Zhang JH, Zhu JH et al.. “Potential of neoadjuvant hepatic artery perfusion chemotherapy in improving surgical outcomes in hepatocellular carcinoma: a systematic review and meta-analysis.” World journal of surgical oncology (2025). PMID: 40442678 ↗
L2aSR_OBSCited in: Future Directions and Emerging Therapies - [235]
Wu S, Gan X, Huang S et al.. “Application and prospect analysis of chimeric antigen receptor T-cell therapy in hepatocellular carcinoma treatment: a systematic review and meta-analysis.” Frontiers in immunology (2025). PMID: 40260256 ↗
L2aSR_OBSCited in: Future Directions and Emerging Therapies - [236]
Kocheise L, Benmebarek MR, Ho M et al.. “Chimeric antigen receptor therapy for hepatocellular carcinoma.” Seminars in immunology (2026). PMID: 41819983 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [237]
Zhang S, Ding L, Hou T et al.. “Hydrogel-Based Immunomodulation of Tumor Immune Microenvironment in Hepatocellular Carcinoma: Current Strategies and Future Directions.” International journal of nanomedicine (2026). PMID: 41810002 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [238]
Shen X, Huang H, Sheng J et al.. “HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications.” Clinical and experimental medicine (2026). PMID: 41673369 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [239]
Jang SH, Kim HS, Eun JW. “RP11-Derived Long Non-Coding RNAs in Hepatocellular Carcinoma: Hidden Treasures in Plain Sight.” Oncology research (2025). PMID: 41502506 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [240]
Usmani A, Siddiqui MA, Mishra A et al.. “Nanovaccines in hepatocellular carcinoma: a new frontier in cancer immunotherapy.” Medical oncology (Northwood, London, England) (2025). PMID: 41452547 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [241]
Nabiyi S, Heiat M, Rezaei E. “Combination therapy strategies targeting glypican-3 in hepatocellular carcinoma: A comprehensive review.” Cytokine & growth factor reviews (2026). PMID: 41406864 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [242]
Dirjayanto VJ, Yiu DSM, Chen R et al.. “Nutrition in Hepatocellular Carcinoma: Pathophysiological Insights, Impact, and Implications for Clinical Practice.” Journal of gastroenterology and hepatology (2026). PMID: 41387249 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [243]
Elahi R, Alami Idrissi Y, Saeed A. “CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation.” Cancer treatment reviews (2025). PMID: 41237439 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [244]
Jia X, Jiang H, Ye Z et al.. “Imaging for molecular and pathological subtyping of hepatocellular carcinoma-a critical appraisal and future directions.” European radiology (2026). PMID: 41168492 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [245]
Liu Y, Zhang M, Huang Y et al.. “Involvement of ferroptosis in metabolic dysfunction-associated steatohepatitis-related liver diseases.” Journal of molecular medicine (Berlin, Germany) (2025). PMID: 41051414 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [246]
Xue J, Zhang J, Chen G et al.. “Advances in Tumor Microenvironment and Immunotherapeutic Strategies for Hepatocellular Carcinoma.” Oncology research (2025). PMID: 40918452 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [247]
Balsano R, Pino M, Bocchero E et al.. “Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions.” Expert opinion on biological therapy (2025). PMID: 40908790 ↗
L2bTRIAL_NONRANDOMCited in: Future Directions and Emerging Therapies - [248]
Zarlashat Y, Ghaffar A, Guerra F et al.. “Immunological Landscape and Molecular Therapeutic Targets of the Tumor Microenvironment in Hepatocellular Carcinoma.” International journal of molecular sciences (2025). PMID: 40869156 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [249]
Li MY, Wu XQ, Lee TKW. “Harnessing the microbiome: unveiling the influence of the gut microbiota on hepatobiliary cancer therapeutic strategies.” Clinical and molecular hepatology (2026). PMID: 40851476 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [250]
Low G, Pfanner T, Qian XJ et al.. “LR-M for CT/MRI on LI-RADS v2018: a review of imaging criteria, performance, challenges and future directions from an end-user perspective.” Abdominal radiology (New York) (2026). PMID: 40810812 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [251]
Philippi Z, Reddy KD, Malik S et al.. “Systemic Therapy for Unresectable Hepatocellular Carcinoma: Current Landscape and Future Directions.” International journal of molecular sciences (2025). PMID: 40649773 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies - [252]
Lewandowski RJ, Serhal M, Padia SA et al.. “The Evolving Application of Radiation Segmentectomy for the Treatment of Hepatic Malignancy.” Radiology (2025). PMID: 40626876 ↗
L5REVIEW_NARRATIVECited in: Future Directions and Emerging Therapies